isoniazid and Disease Models, Animal studies

Hydra: A genus of freshwater polyps in the family Hydridae, order Hydroida, class HYDROZOA. They are of special interest because of their complex organization and because their adult organization corresponds roughly to the gastrula of higher animals.
hydrazide : Compounds derived from oxoacids RkE(=O)l(OH)m (l =/= 0) by replacing -OH by -NRNR2 (R groups are commonly H). (IUPAC).

Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.

Research Excerpts

Excerpt	Relevance	Reference
"TBI-166, derived from riminophenazine analogues, shows more potent anti-TB activity than clofazimine and is being assessed against tuberculosis (TB) in a phase IIa clinical trial in China."	8.12	Superior Efficacy of a TBI-166, Bedaquiline, and Pyrazinamide Combination Regimen in a Murine Model of Tuberculosis. ( Chen, X; Ding, Y; Fu, L; Guo, S; Liu, H; Lu, Y; Wang, B; Wang, N; Zhang, W; Zhu, H, 2022)
" Here, two murine models of tuberculosis were used to test whether novel regimens replacing rifapentine and isoniazid with bedaquiline and another drug would maintain or increase the sterilizing activity of the regimen."	8.12	Novel Regimens of Bedaquiline-Pyrazinamide Combined with Moxifloxacin, Rifabutin, Delamanid and/or OPC-167832 in Murine Tuberculosis Models. ( Carr, W; Converse, PJ; Dartois, V; Dooley, KE; Garcia, A; Kurbatova, E; Nuermberger, EL; Stout, JE; Tasneen, R; Vernon, AA; Zimmerman, MD, 2022)
"Niacin deficiency causes pellagra, the symptoms of which include dermatitis, diarrhoea and dementia."	8.12	Effect of niacin supplementation on nausea-like behaviour in an isoniazid-induced mouse model of pellagra. ( Ishikawa, T; Kuroita, T; Kuronuma, K; Natsumi, S; Yoshioka, T, 2022)
"Experimental and clinical studies have indicated that the antileprosy drug clofazimine may contribute treatment-shortening activity when included in tuberculosis treatment regimens."	7.83	Clofazimine Contributes Sustained Antimicrobial Activity after Treatment Cessation in a Mouse Model of Tuberculosis Chemotherapy. ( Adamson, J; Almeida, DV; Ammerman, NC; Bester, LA; Dorasamy, A; Grosset, JH; Mgaga, Z; Moodley, C; Moodley, S; Ngcobo, B; Singh, SD; Swanson, RV, 2016)
"Assessment of the activity of thioridazine towards Mycobacterium tuberculosis (Mtb), in vitro and in vivo as a single drug and in combination with tuberculosis (TB) drugs."	7.80	Enhancement of in vitro activity of tuberculosis drugs by addition of thioridazine is not reflected by improved in vivo therapeutic efficacy. ( Aarnoutse, R; Bakker-Woudenberg, IA; Boeree, MJ; de Knegt, GJ; de Steenwinkel, JE; ten Kate, MT; van Soolingen, D, 2014)
"Standard tuberculosis (TB) treatment includes an initial regimen containing drugs that are both rapidly bactericidal (isoniazid) and sterilizing (rifampin and pyrazinamide), and ethambutol to help prevent the emergence of drug resistance."	7.78	Modeling early bactericidal activity in murine tuberculosis provides insights into the activity of isoniazid and pyrazinamide. ( Almeida, D; Ammerman, NC; Bishai, WR; Converse, PJ; Grosset, J; Hafner, R; Lalloo, U; Li, SY; Pym, AS; Swindells, S; Tyagi, S; Wallengren, K, 2012)
"These results suggest that regimens consisting of isoniazid or moxifloxacin plus rifapentine and pyrazinamide may dramatically shorten the duration of treatment needed to cure human tuberculosis."	7.74	Isoniazid or moxifloxacin in rifapentine-based regimens for experimental tuberculosis? ( Almeida, D; Grosset, JH; Nuermberger, EL; Rosenthal, IM; Zhang, M, 2008)
"To assess the impact of iron loading on the activity of isoniazid and ethambutol in the treatment of murine tuberculosis."	7.72	Impact of iron loading on the activity of isoniazid or ethambutol in the treatment of murine tuberculosis. ( Boelaert, RJ; Grosset, J; Lounis, N; Maslo, C; Truffot-Pernot, C, 2003)
"Rifapentine is a long-acting rifamycin which may be useful for intermittent drug therapy against tuberculosis."	7.70	Analysis of rifapentine for preventive therapy in the Cornell mouse model of latent tuberculosis. ( Bishai, WR; Chaisson, RE; Miyazaki, E, 1999)
"To establish the chemotherapeutic value of a depot drug preparation of isoniazid and pyrazinamide against experimental tuberculosis."	7.70	Chemotherapy of tuberculosis in mice using single implants of isoniazid and pyrazinamide. ( Gangadharam, PR; Geeta, N; Hsu, YY; Wise, DL, 1999)
" In this study, we evaluated the ability of rifapentine (RFP), in monotherapy and combination therapy, to completely eradicate a Mycobacterium tuberculosis infection and to prevent relapse posttreatment in a Swiss mouse model."	7.70	Evaluation of rifapentine in long-term treatment regimens for tuberculosis in mice. ( Chase, SE; Chmielewski, AJ; Cynamon, MH; Lenaerts, AM, 1999)
"Tuberculosis is a leading cause of death worldwide."	5.56	Inhalable locust bean gum microparticles co-associating isoniazid and rifabutin: Therapeutic assessment in a murine model of tuberculosis infection. ( Almeida, AJ; Alves, AD; Gaspar, MM; Grenha, A; Guerreiro, F; Pinho, J; Simões, S, 2020)
"Tuberculosis is a major global health problem for which improved therapeutics are needed to shorten the course of treatment and combat emergence of drug resistance."	5.42	pH-Responsive Isoniazid-Loaded Nanoparticles Markedly Improve Tuberculosis Treatment in Mice. ( Clemens, DL; Dillon, BJ; Horwitz, MA; Hwang, AA; Lee, BY; Zink, JI, 2015)
"tuberculosis have been developed."	5.42	Cell division inhibitors with efficacy equivalent to isoniazid in the acute murine Mycobacterium tuberculosis infection model. ( Awasthi, D; Carreau, A; Goullieux, L; Knudson, SE; Kumar, K; Lagrange, S; Ojima, I; Slayden, RA; Vermet, H, 2015)
" However, further studies to identify the optimal statin and dosing are required."	5.40	Simvastatin increases the in vivo activity of the first-line tuberculosis regimen. ( Bruiners, N; Gennaro, ML; Karakousis, PC; Pine, R; Pinn, ML; Skerry, C, 2014)
"Further, a murine model of latent tuberculosis was used and the standard 9-month isoniazid and 4-month rifampicin regimen along with thioridazine as an adjunct drug were evaluated."	5.40	Chemotherapeutic efficacy of thioridazine as an adjunct drug in a murine model of latent tuberculosis. ( Sharma, S; Singh, A, 2014)
"Rifapentine is a long-lived rifamycin derivative currently recommended only in once-weekly continuation-phase regimens."	5.34	Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model. ( Bishai, WR; Chaisson, RE; Grosset, JH; Nuermberger, EL; Peloquin, CA; Rosenthal, IM; Tyagi, S; Vernon, AA; Williams, KN; Zhang, M, 2007)
" Here, two murine models of tuberculosis were used to test whether novel regimens replacing rifapentine and isoniazid with bedaquiline and another drug would maintain or increase the sterilizing activity of the regimen."	4.12	Novel Regimens of Bedaquiline-Pyrazinamide Combined with Moxifloxacin, Rifabutin, Delamanid and/or OPC-167832 in Murine Tuberculosis Models. ( Carr, W; Converse, PJ; Dartois, V; Dooley, KE; Garcia, A; Kurbatova, E; Nuermberger, EL; Stout, JE; Tasneen, R; Vernon, AA; Zimmerman, MD, 2022)
"TBI-166, derived from riminophenazine analogues, shows more potent anti-TB activity than clofazimine and is being assessed against tuberculosis (TB) in a phase IIa clinical trial in China."	4.12	Superior Efficacy of a TBI-166, Bedaquiline, and Pyrazinamide Combination Regimen in a Murine Model of Tuberculosis. ( Chen, X; Ding, Y; Fu, L; Guo, S; Liu, H; Lu, Y; Wang, B; Wang, N; Zhang, W; Zhu, H, 2022)
"Niacin deficiency causes pellagra, the symptoms of which include dermatitis, diarrhoea and dementia."	4.12	Effect of niacin supplementation on nausea-like behaviour in an isoniazid-induced mouse model of pellagra. ( Ishikawa, T; Kuroita, T; Kuronuma, K; Natsumi, S; Yoshioka, T, 2022)
"Experimental and clinical studies have indicated that the antileprosy drug clofazimine may contribute treatment-shortening activity when included in tuberculosis treatment regimens."	3.83	Clofazimine Contributes Sustained Antimicrobial Activity after Treatment Cessation in a Mouse Model of Tuberculosis Chemotherapy. ( Adamson, J; Almeida, DV; Ammerman, NC; Bester, LA; Dorasamy, A; Grosset, JH; Mgaga, Z; Moodley, C; Moodley, S; Ngcobo, B; Singh, SD; Swanson, RV, 2016)
"Mycobacterium tuberculosis-infected mice in the chronic phase of the disease (day 30) received: (i) isoniazid and rifampicin (drugs) daily for 30 days; (ii) DNA immunotherapy (DNA), consisting of four 100 μg injections at 10 day intervals; (iii) both therapies (DNA + drugs); or (iv) saline."	3.81	Synergy of chemotherapy and immunotherapy revealed by a genome-scale analysis of murine tuberculosis. ( Arnoldi, FG; Brandão, IT; Cagnard, N; Chiocchia, G; Jacques, S; Letourneur, F; Masson, AP; Ramos, SG; Rios, WM; Rodrigues, RF; Silva, CL; Soares, LS; Souza, PR; Zárate-Bladés, CR, 2015)
"Assessment of the activity of thioridazine towards Mycobacterium tuberculosis (Mtb), in vitro and in vivo as a single drug and in combination with tuberculosis (TB) drugs."	3.80	Enhancement of in vitro activity of tuberculosis drugs by addition of thioridazine is not reflected by improved in vivo therapeutic efficacy. ( Aarnoutse, R; Bakker-Woudenberg, IA; Boeree, MJ; de Knegt, GJ; de Steenwinkel, JE; ten Kate, MT; van Soolingen, D, 2014)
"To explain why the efficacies of isoniazid (INH) and rifamycins during the treatment of tuberculosis (TB) are related not to the area under the curve (AUC)/minimum inhibitory concentration (MIC), but to peak drug concentrations."	3.78	Pharmacokinetic/pharmacodynamic parameters and the choice of high-dosage rifamycins. ( Mitchison, DA, 2012)
"Standard tuberculosis (TB) treatment includes an initial regimen containing drugs that are both rapidly bactericidal (isoniazid) and sterilizing (rifampin and pyrazinamide), and ethambutol to help prevent the emergence of drug resistance."	3.78	Modeling early bactericidal activity in murine tuberculosis provides insights into the activity of isoniazid and pyrazinamide. ( Almeida, D; Ammerman, NC; Bishai, WR; Converse, PJ; Grosset, J; Hafner, R; Lalloo, U; Li, SY; Pym, AS; Swindells, S; Tyagi, S; Wallengren, K, 2012)
"We have previously demonstrated a potent in vitro inhibitory activity for two pentacyano(isoniazid)ferrate(II) compounds, namely IQG-607 and IQG-639, against the Mycobacterium tuberculosis enoyl-acyl carrier protein reductase enzyme."	3.78	Activity of IQG-607, a new orally active compound, in a murine model of Mycobacterium tuberculosis infection. ( Basso, LA; Calixto, JB; Campos, MM; de França Lopes, LG; Dos Santos Junior, A; Dos Santos, AJ; Rodrigues-Junior, VS; Santos, DS; Schneider, CZ; Sousa, EH; Souto, AA, 2012)
" Between day 52 and 5 mo after infection, 10 of the 170 mice infected according to this protocol developed torticollis, including mice in treatment groups that received combination antibiotic therapy of rifampin-pyrazinamide or moxifloxacin-rifampin-pyrazinamide."	3.77	Torticollis in mice intravenously infected with Mycobacterium tuberculosis. ( DeGroote, MA; Gilliland, JC; Kendall, LV; Lenaerts, AJ; Magden, ER; Weiner, CM, 2011)
" We show that Mtb continues to acquire mutations during disease latency, which may explain why isoniazid monotherapy for latent tuberculosis is a risk factor for the emergence of isoniazid resistance."	3.77	Use of whole genome sequencing to estimate the mutation rate of Mycobacterium tuberculosis during latent infection. ( Chase, MR; Flynn, JL; Ford, CB; Fortune, SM; Galagan, J; Iartchouk, O; Ioerger, TR; Lin, PL; Lipsitch, M; Mohaideen, N; Sacchettini, JC; Shah, RR, 2011)
"These results suggest that regimens consisting of isoniazid or moxifloxacin plus rifapentine and pyrazinamide may dramatically shorten the duration of treatment needed to cure human tuberculosis."	3.74	Isoniazid or moxifloxacin in rifapentine-based regimens for experimental tuberculosis? ( Almeida, D; Grosset, JH; Nuermberger, EL; Rosenthal, IM; Zhang, M, 2008)
"Reduction of colony forming units by rifampicin-isoniazid therapy given 9-17 weeks post-infection was made more pronounced by immunotherapy with a vaccine made of fragmented Mycobacterium tuberculosis cells detoxified and liposomed (RUTI), given on weeks 17, 19 and 21 post-infection, in the murine model of tuberculosis in C57BL/6 and DBA/2 inbred strains."	3.73	Immunotherapy with fragmented Mycobacterium tuberculosis cells increases the effectiveness of chemotherapy against a chronical infection in a murine model of tuberculosis. ( Amat, I; Arcos, V; Ausina, V; Cardona, PJ; Díaz, J; Gordillo, S; Guirado, E; Tapia, G; Vilaplana, C, 2005)
"To assess the impact of iron loading on the activity of isoniazid and ethambutol in the treatment of murine tuberculosis."	3.72	Impact of iron loading on the activity of isoniazid or ethambutol in the treatment of murine tuberculosis. ( Boelaert, RJ; Grosset, J; Lounis, N; Maslo, C; Truffot-Pernot, C, 2003)
"The capacity to generate a chronic and persistent infection in the experimental murine model of tuberculosis induced aerogenically by a low-dose inoculum was determined in eight isoniazid-resistant clinical strains of Mycobacterium tuberculosis showing different catalase-peroxidase (C-P) activities."	3.72	Catalase-peroxidase activity has no influence on virulence in a murine model of tuberculosis. ( Amat, I; Ariza, A; Ausina, V; Cardona, PJ; Díaz, J; Gordillo, S; Llatjós, R; Lonca, J; Pallarés, A; Vilaplana, C, 2003)
"To establish the chemotherapeutic value of a depot drug preparation of isoniazid and pyrazinamide against experimental tuberculosis."	3.70	Chemotherapy of tuberculosis in mice using single implants of isoniazid and pyrazinamide. ( Gangadharam, PR; Geeta, N; Hsu, YY; Wise, DL, 1999)
"Rifapentine is a long-acting rifamycin which may be useful for intermittent drug therapy against tuberculosis."	3.70	Analysis of rifapentine for preventive therapy in the Cornell mouse model of latent tuberculosis. ( Bishai, WR; Chaisson, RE; Miyazaki, E, 1999)
" In this study, we evaluated the ability of rifapentine (RFP), in monotherapy and combination therapy, to completely eradicate a Mycobacterium tuberculosis infection and to prevent relapse posttreatment in a Swiss mouse model."	3.70	Evaluation of rifapentine in long-term treatment regimens for tuberculosis in mice. ( Chase, SE; Chmielewski, AJ; Cynamon, MH; Lenaerts, AM, 1999)
" The onset of isoniazid-induced seizures in LEC rats at 9 weeks of age was significantly delayed compared with that in LE rats."	3.70	Increased abundance of GABAA receptor subunit mRNAs in the brain of Long-Evans Cinnamon rats, an animal model of Wilson's disease. ( Biggio, G; Floris, S; Follesa, P; Mallei, A; Mostallino, MC; Sanna, E, 1999)
"The effect of lomefloxacin was studied on mice with experimental infection due to Mycobacterium tuberculosis."	3.69	[Antitubercular activity of lomefloxacin in an experiment]. ( Makarova, OV; Mikhaĭlova, LP; Mozhokina, GN; Sokolova, GB, 1996)
" PubMed, Ovid MEDLINE and EMBASE were systematically searched for publications in English to evaluate the evidence about dosing schedules and treatment efficacy."	2.47	Treatment of tuberculosis and optimal dosing schedules. ( Chang, KC; Grosset, J; Leung, CC; Yew, WW, 2011)
"All rabbits in group A were treated by INH-RFP-BSA-NPs's injection and in group B were treated with classic dosage form of INH and RFP, while in group C normal saline was given as the blank control."	1.72	Treatment of spinal tuberculosis in rabbits using bovine serum albumin nanoparticles loaded with isoniazid and rifampicin. ( Chen, Z; Ge, Z; Liang, S; Liu, X; Ma, H; Ma, R; Wu, P; Zhang, J, 2022)
"New effective compounds to treat tuberculosis are urgently needed."	1.56	Nonclinical evaluation of IQG-607, an anti-tuberculosis candidate with potential use in combination drug therapy. ( Abbadi, BL; Basso, LA; Bizarro, CV; Bondan da Silva, J; Machado, P; Picada, JN; Pissinate, K; Rodrigues-Junior, VS; Sperotto, NDM; Villela, AD, 2020)
"Tuberculosis is a leading cause of death worldwide."	1.56	Inhalable locust bean gum microparticles co-associating isoniazid and rifabutin: Therapeutic assessment in a murine model of tuberculosis infection. ( Almeida, AJ; Alves, AD; Gaspar, MM; Grenha, A; Guerreiro, F; Pinho, J; Simões, S, 2020)
"tuberculosis (TB)."	1.51	Results of a pilot study of isoniazid in patients with erythropoietic protoporphyria. ( Anderson, KE; Balwani, M; Bissel, MD; Bloomer, JR; Desnick, RJ; Gouya, L; Parker, CJ; Phillips, JD; Puy, H; Singal, A, 2019)
"In the treatment of murine tuberculosis, a rifampicin dose of 30 mg/kg was sufficient to eradicate persistent M."	1.48	Optimal doses of rifampicin in the standard drug regimen to shorten tuberculosis treatment duration and reduce relapse by eradicating persistent bacteria. ( Alameda-Martin, L; Coates, A; Davies, G; Harrison, T; Hu, Y; Liu, Y; Ortega-Muro, F; Pertinez, H, 2018)
" Compound 10a also displayed good pharmacokinetic profiles with oral bioavailability (F) of 41."	1.43	Discovery of new chemical entities as potential leads against Mycobacterium tuberculosis. ( Ding, K; Li, M; Liu, Z; Lu, X; Tang, J; Zhang, T; Zhang, X, 2016)
"Pyrazinamide (PZA) is a key sterilizing drug in first-line tuberculosis (TB) regimens and exerts its activity entirely during the first 2 months in human infections."	1.43	Sterilizing Activity of Pyrazinamide in Combination with First-Line Drugs in a C3HeB/FeJ Mouse Model of Tuberculosis. ( Betoudji, F; Lanoix, JP; Nuermberger, E, 2016)
" The relative bias and relative imprecision of each pharmacokinetic parameter for each drug were derived and assessed to choose the final designs."	1.43	Population pharmacokinetics, optimised design and sample size determination for rifampicin, isoniazid, ethambutol and pyrazinamide in the mouse. ( Alameda, L; Chen, C; Ferrer, S; Ortega, F; Simonsson, US, 2016)
"Tuberculosis is a major global health problem for which improved therapeutics are needed to shorten the course of treatment and combat emergence of drug resistance."	1.42	pH-Responsive Isoniazid-Loaded Nanoparticles Markedly Improve Tuberculosis Treatment in Mice. ( Clemens, DL; Dillon, BJ; Horwitz, MA; Hwang, AA; Lee, BY; Zink, JI, 2015)
"tuberculosis have been developed."	1.42	Cell division inhibitors with efficacy equivalent to isoniazid in the acute murine Mycobacterium tuberculosis infection model. ( Awasthi, D; Carreau, A; Goullieux, L; Knudson, SE; Kumar, K; Lagrange, S; Ojima, I; Slayden, RA; Vermet, H, 2015)
"Further, a murine model of latent tuberculosis was used and the standard 9-month isoniazid and 4-month rifampicin regimen along with thioridazine as an adjunct drug were evaluated."	1.40	Chemotherapeutic efficacy of thioridazine as an adjunct drug in a murine model of latent tuberculosis. ( Sharma, S; Singh, A, 2014)
" In this study, we sought to investigate the sterilizing activity of human-equivalent doses of thioridazine when given in combination with the "Denver regimen" against acute murine tuberculosis."	1.40	Sterilizing activity of thioridazine in combination with the first-line regimen against acute murine tuberculosis. ( Dutta, NK; Karakousis, PC; Pinn, ML, 2014)
" However, further studies to identify the optimal statin and dosing are required."	1.40	Simvastatin increases the in vivo activity of the first-line tuberculosis regimen. ( Bruiners, N; Gennaro, ML; Karakousis, PC; Pine, R; Pinn, ML; Skerry, C, 2014)
" This is despite the availability of antibiotics that have good activity against Mycobacterium tuberculosis in vitro and favorable pharmacokinetic profiles in plasma."	1.38	Pharmacokinetic evaluation of the penetration of antituberculosis agents in rabbit pulmonary lesions. ( Barry, CE; Dartois, V; Goh, A; Kern, S; Kjellsson, MC; Low, KM; Pillai, G; Via, LE; Weiner, D, 2012)
" Noncompliance treatment, simulated by a reduced duration and dosing frequency, resulted in a relapse of infection."	1.38	Consequences of noncompliance for therapy efficacy and emergence of resistance in murine tuberculosis caused by the Beijing genotype of Mycobacterium tuberculosis. ( Aarnoutse, RE; Bakker-Woudenberg, IA; Boeree, MJ; de Knegt, GJ; de Steenwinkel, JE; den Bakker, MA; ten Kate, MT; van Soolingen, D; Verbrugh, HA, 2012)
"Metronidazole (MTZ), which has activity only against anaerobic, nonreplicating bacteria, was as effective as either of these treatments in preventing reactivation of latent infection."	1.38	Metronidazole prevents reactivation of latent Mycobacterium tuberculosis infection in macaques. ( Barry, CE; Dartois, V; Flynn, JL; Goodwin, MB; Janssen, C; Johnston, PJ; Klein, E; Lin, PL; Via, L, 2012)
"Rifampin-treated BALB/c mice remained culture positive at 3 months."	1.37	Treatment of tuberculosis with rifamycin-containing regimens in immune-deficient mice. ( Ahmad, Z; Almeida, DV; Converse, PJ; Grosset, JH; Li, SY; Nuermberger, EL; Peloquin, CA; Rosenthal, IM; Zhang, M, 2011)
"Mycobacterium tuberculosis is the causative agent of a pulmonary epidemic that is estimated to infect one-third of the world's population and that has an increased incidence of multidrug resistance."	1.37	T cell monitoring of chemotherapy in experimental rat tuberculosis. ( Bifani, P; Camacho, L; Dartois, V; Foo, DG; Hervé, M; Siew, JY; Singhal, A; Tay, HC, 2011)
" For the first 2 weeks of therapy, the dosing frequency was 5 days/week, and for the remaining period, twice weekly."	1.36	Comparison of the 'Denver regimen' against acute tuberculosis in the mouse and guinea pig. ( Ahmad, Z; Grosset, JH; Karakousis, PC; Nuermberger, EL; Peloquin, CA; Pinn, ML; Tasneen, R; Williams, KN, 2010)
"Coexistence of pulmonary tuberculosis (TB) and lung cancer in clinic poses significant challenges for the diagnostic and treatment of both diseases."	1.35	Lung carcinogenesis induced by chronic tuberculosis infection: the experimental model and genetic control. ( Bronson, RT; Kramnik, I; Nalbandian, A; Pichugin, A; Yan, BS, 2009)
"Erdosteine was treated orally for 15 days at a dose of 10 mg/kg/day."	1.35	Protective role of caffeic acid phenethyl ester and erdosteine on activities of purine-catabolizing enzymes and level of nitric oxide in red blood cells of isoniazid-administered rats. ( Ciçek, E; Gökalp, O; Ozçelik, N; Ozer, MK; Uz, E; Yilmaz, HR, 2008)
"Treatment with rifampin and pyrazinamide was more effective than treatment with rifampin, isoniazid, and pyrazinamide at reducing the lung CFU count, consistent with past evidence of isoniazid's antagonism in this model."	1.35	Enhanced bactericidal activity of rifampin and/or pyrazinamide when combined with PA-824 in a murine model of tuberculosis. ( Grosset, J; Nuermberger, E; Tasneen, R; Tyagi, S; Williams, K, 2008)
"Isoniazid is a widely used drug for the treatment of tuberculosis, but hepatotoxicity is a major concern during treatment."	1.35	Protective effects of thiopronin against isoniazid-induced hepatotoxicity in rats. ( Chen, J; Dong, G; He, C; Liu, Y; Peng, R; Yue, J, 2009)
"Rifapentine is a long-lived rifamycin derivative currently recommended only in once-weekly continuation-phase regimens."	1.34	Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model. ( Bishai, WR; Chaisson, RE; Grosset, JH; Nuermberger, EL; Peloquin, CA; Rosenthal, IM; Tyagi, S; Vernon, AA; Williams, KN; Zhang, M, 2007)
" The effective therapeutic dosage of drugs could be reduced to half by supplementing HNP-1 in the therapeutic schedule."	1.32	Role of human neutrophil peptide-1 as a possible adjunct to antituberculosis chemotherapy. ( Kalita, A; Khuller, GK; Verma, I, 2004)
"Rifalazil (formerly known as KRM-1648) in combination with isoniazid has been found to be more active than rifampin/isoniazid."	1.31	Durable cure for tuberculosis: rifalazil in combination with isoniazid in a murine model of Mycobacterium tuberculosis infection. ( Cynamon, MH; DeStefano, MS; Shoen, CM, 2000)
"When thalidomide treatment was combined with antibiotics, there was a marked reduction in TNF-alpha levels, leukocytosis, and brain pathology."	1.30	A combination of thalidomide plus antibiotics protects rabbits from mycobacterial meningitis-associated death. ( Freedman, VH; Kaplan, G; Sokol, K; Tsenova, L, 1998)
"tuberculosis are treated with antibiotics (isoniazid and pyrazinamide), resulting in no detectable bacilli by organ culture."	1.30	Reactivation of latent tuberculosis: variations on the Cornell murine model. ( Chan, J; Flynn, JL; Joseph, H; Mohan, VP; Scanga, CA; Yu, K, 1999)
" Unfortunately, INH is associated with significant hepatotoxicity in up to 2% of individuals exposed, and if this adverse event is not recognized early it can be fatal."	1.29	A model of isoniazid-induced hepatotoxicity in rabbits. ( Adams, SP; Bain, AI; Sarich, TC; Wall, RA; Wright, JM; Zhou, T, 1995)
"Dimephosphon was found to be responsible for both the in vivo and in vitro decrease of the degree of MBT resistance to rifampicin."	1.28	[Use of dimephosphon in pathogenetic therapy of experimental tuberculosis]. ( Aleksandrova, AE; Shchegoleva, RA; Shcherbakova, NM; Zabolotnykh, NV, 1991)

Research

Studies (195)

Authors

Clinical Trials (4)

Trial Overview

Trial Outcomes

Number of Clinically Relevant Abnormalities in the Laboratory Tests According to the Doctors' Impression

Timeframe	Studies, this research(%)	All Research%
pre-1990	25 (12.82)	18.7374
1990's	20 (10.26)	18.2507
2000's	44 (22.56)	29.6817
2010's	83 (42.56)	24.3611
2020's	23 (11.79)	2.80

Authors	Studies
Vicente, E	1
Villar, R	1
Burguete, A	1
Solano, B	1
Pérez-Silanes, S	1
Aldana, I	1
Maddry, JA	1
Lenaerts, AJ	5
Franzblau, SG	2
Cho, SH	1
Monge, A	1
Goldman, RC	1
O'Donnell, G	1
Poeschl, R	1
Zimhony, O	1
Gunaratnam, M	1
Moreira, JB	1
Neidle, S	1
Evangelopoulos, D	2
Bhakta, S	1
Malkinson, JP	1
Boshoff, HI	1
Lenaerts, A	1
Gibbons, S	1
Rullas, J	1
García, JI	1
Beltrán, M	1
Cardona, PJ	5
Cáceres, N	3
García-Bustos, JF	1
Angulo-Barturen, I	1
Bogatcheva, E	1
Hanrahan, C	1
Nikonenko, B	1
de los Santos, G	1
Reddy, V	1
Chen, P	1
Barbosa, F	1
Einck, L	1
Nacy, C	1
Protopopova, M	1
Yang, Y	1
Wang, Z	1
Yang, J	1
Yang, T	1
Pi, W	1
Ang, W	1
Lin, Y	1
Liu, Y	5
Li, Z	1
Luo, Y	1
Wei, Y	1
Kale, MG	2
Raichurkar, A	2
P, SH	1
Waterson, D	2
McKinney, D	1
Manjunatha, MR	3
Kranthi, U	1
Koushik, K	2
Jena, Lk	3
Shinde, V	2
Rudrapatna, S	1
Barde, S	1
Humnabadkar, V	3
Madhavapeddi, P	2
Basavarajappa, H	2
Ghosh, A	1
Ramya, VK	1
Guptha, S	1
Sharma, S	7
Vachaspati, P	1
Kumar, KN	1
Giridhar, J	1
Reddy, J	2
Panduga, V	2
Ganguly, S	2
Ahuja, V	2
Gaonkar, S	2
Kumar, CN	1
Ogg, D	2
Tucker, JA	1
Boriack-Sjodin, PA	2
de Sousa, SM	2
Sambandamurthy, VK	3
Ghorpade, SR	2
Kale, RR	1
Hameed, SP	1
Kishore Reddy, BK	1
Malolanarasimhan, K	1
Menasinakai, S	1
Nandishaiah, R	1
Mahesh Kumar, KN	1
Naveen Kumar, CN	1
Shirude, PS	1
Shandil, RK	1
Sadler, C	1
Panda, M	1
Saralaya, R	1
Nanduri, R	1
Ambady, A	1
Ravishankar, S	1
Suresh, RS	1
Srivastava, A	1
Prabhakar, KR	1
Whiteaker, J	1
McLaughlin, RE	1
Cooper, CB	1
Mdluli, K	2
Butler, S	1
Iyer, PS	1
Narayanan, S	1
Chatterji, M	1
Seebacher, W	1
Wolkinger, V	1
Faist, J	1
Kaiser, M	1
Brun, R	1
Saf, R	1
Bucar, F	1
Gröblacher, B	1
Brantner, A	1
Merino, V	1
Kalia, Y	1
Scapozza, L	1
Perozzo, R	1
Weis, R	1
Stec, J	1
Onajole, OK	1
Lun, S	1
Guo, H	1
Merenbloom, B	1
Vistoli, G	2
Bishai, WR	8
Kozikowski, AP	1
Lu, X	2
Tang, J	2
Cui, S	1
Wan, B	1
Franzblauc, SG	1
Zhang, T	2
Zhang, X	2
Ding, K	2
Liu, Z	2
Li, M	1
Poce, G	1
Cocozza, M	1
Alfonso, S	1
Consalvi, S	1
Venditti, G	1
Fernandez-Menendez, R	1
Bates, RH	1
Barros Aguirre, D	1
Ballell, L	1
De Logu, A	1
Biava, M	1
Abrams, RPM	1
Yasgar, A	1
Teramoto, T	1
Lee, MH	1
Dorjsuren, D	1
Eastman, RT	1
Malik, N	1
Zakharov, AV	1
Li, W	2
Bachani, M	1
Brimacombe, K	1
Steiner, JP	1
Hall, MD	1
Balasubramanian, A	1
Jadhav, A	1
Padmanabhan, R	1
Simeonov, A	1
Nath, A	1
Ang, CW	1
Lee, BM	1
Jackson, CJ	1
Wang, Y	1
Francisco, AF	1
Kelly, JM	1
Bernhardt, PV	1
Tan, L	1
West, NP	1
Sykes, ML	1
Hinton, AO	1
Bolisetti, R	1
Avery, VM	1
Cooper, MA	1
Blaskovich, MAT	1
Li, Y	2
Li, L	1
Sha, X	1
Zhang, K	1
Li, G	1
Ma, Y	1
Zhou, J	1
Hao, Y	2
Zhang, Z	1
Cui, X	1
Tang, PF	1
Wang, L	3
Wang, H	1
Ma, R	1
Zhang, J	2
Chen, Z	1
Ma, H	1
Liu, X	1
Liang, S	1
Wu, P	1
Ge, Z	1
Tasneen, R	4
Garcia, A	1
Converse, PJ	3
Zimmerman, MD	1
Dartois, V	7
Kurbatova, E	1
Vernon, AA	2
Carr, W	1
Stout, JE	1
Dooley, KE	1
Nuermberger, EL	7
Ding, Y	1
Zhu, H	2
Fu, L	2
Zhang, W	2
Wang, B	2
Guo, S	1
Chen, X	1
Wang, N	1
Liu, H	1
Lu, Y	2
Glenn, SM	1
Turapov, O	1
Makarov, V	2
Kell, DB	1
Mukamolova, GV	1
Parker, CJ	1
Desnick, RJ	1
Bissel, MD	1
Bloomer, JR	1
Singal, A	1
Gouya, L	1
Puy, H	1
Anderson, KE	1
Balwani, M	1
Phillips, JD	1
Batalha, IL	1
Bernut, A	1
Schiebler, M	1
Ouberai, MM	1
Passemar, C	1
Klapholz, C	1
Kinna, S	1
Michel, S	1
Sader, K	1
Castro-Hartmann, P	1
Renshaw, SA	1
Welland, ME	1
Floto, RA	1
Mir, SA	1
He, X	1
Song, Y	1
Xu, J	2
Grenha, A	1
Alves, AD	1
Guerreiro, F	1
Pinho, J	1
Simões, S	1
Almeida, AJ	1
Gaspar, MM	1
Rodrigues-Junior, VS	2
Villela, AD	1
Abbadi, BL	1
Sperotto, NDM	1
Pissinate, K	1
Picada, JN	1
Bondan da Silva, J	1
Bizarro, CV	1
Machado, P	1
Basso, LA	2
Shkurupy, VA	2
Cherdantseva, LA	2
Kovner, AV	2
Troitskii, AV	1
Bystrova, TN	1
Starostenko, AA	2
Troitskiy, AV	1
Bystrova, AV	1
Negi, S	1
Pahari, S	1
Bashir, H	1
Agrewala, JN	1
Bhaskar, A	1
Kumari, A	1
Singh, M	1
Kumar, S	2
Dabla, A	1
Chaturvedi, S	1
Yadav, V	1
Chattopadhyay, D	1
Prakash Dwivedi, V	1
De Falco, A	1
Kincheski, GC	1
Atrián-Blasco, E	1
Hureau, C	1
Ferreira, ST	1
Rey, NA	1
Pan, Y	1
Tang, P	1
Cao, J	1
Song, Q	1
Zhu, L	1
Ma, S	1
Çelik, H	1
Kucukler, S	1
Çomaklı, S	1
Caglayan, C	1
Özdemir, S	1
Yardım, A	1
Karaman, M	1
Kandemir, FM	1
Sharma, V	1
Kaur, R	1
Sharma, VL	1
Chakraborty, P	1
Bajeli, S	1
Kaushal, D	1
Radotra, BD	1
Kumar, A	1
Yaghoubi, A	1
Davoodi, J	1
Asgharzadeh, F	1
Rezaie, S	1
Nazari, E	1
Khazaei, M	1
Soleimanpour, S	1
Natsumi, S	1
Kuroita, T	1
Ishikawa, T	1
Kuronuma, K	1
Yoshioka, T	1
Dumouchel, JL	1
Kramlinger, VM	1
Dutta, NK	5
Pinn, ML	6
Karakousis, PC	11
de Knegt, GJ	4
Dickinson, L	1
Pertinez, H	4
McHugh, TD	1
Bakker-Woudenberg, IAJM	1
Davies, GR	2
de Steenwinkel, JEM	2
Mourik, BC	1
Verbon, A	1
Mouton, JW	1
Bax, HI	1
Gengenbacher, M	1
Duque-Correa, MA	1
Kaiser, P	1
Schuerer, S	1
Lazar, D	1
Zedler, U	1
Reece, ST	1
Nayyar, A	1
Cole, ST	1
Barry Iii, CE	1
Kaufmann, SHE	1
Ortega-Muro, F	2
Alameda-Martin, L	2
Harrison, T	1
Davies, G	2
Coates, A	2
Hu, Y	3
Vilchèze, C	1
Kim, J	1
Jacobs, WR	1
Gillespie, SH	1
Coates, AR	1
Benmerzoug, S	1
Marinho, FV	1
Rose, S	1
Mackowiak, C	1
Gosset, D	1
Sedda, D	1
Poisson, E	1
Uyttenhove, C	1
Van Snick, J	1
Jacobs, M	1
Garcia, I	1
Ryffel, B	1
Quesniaux, VFJ	1
Robertson, GT	1
Ektnitphong, VA	1
Scherman, MS	1
McNeil, MB	1
Dennison, D	1
Korkegian, A	1
Smith, AJ	1
Halladay, J	1
Carter, DS	1
Xia, Y	1
Zhou, Y	1
Choi, W	1
Berry, PW	1
Mao, W	1
Hernandez, V	1
Alley, MRK	1
Parish, T	1
Khan, N	1
Mendonca, L	1
Dhariwal, A	1
Fontes, G	1
Menzies, D	1
Xia, J	1
Divangahi, M	1
King, IL	1
Pisu, MG	1
Boero, G	1
Garau, A	1
Casula, C	1
Cisci, S	1
Biggio, F	1
Concas, A	1
Follesa, P	2
Maciocco, E	1
Porcu, P	1
Serra, M	1
Hussain, T	1
Gupta, RK	1
K, S	1
Khan, MS	1
Hussain, MD	1
Arif, MD	1
Hussain, A	1
Faiyazuddin, MD	1
Rao, CV	1
Chuang, YM	2
Belchis, DA	1
Wang, P	1
Bai, Y	1
Kang, J	1
Luo, T	1
Shi, C	1
Xu, Z	1
Metushi, IG	2
Uetrecht, J	2
Jaydeokar, AV	1
Bandawane, DD	1
Bibave, KH	1
Patil, TV	1
Skerry, C	1
Bruiners, N	1
Pine, R	1
Gennaro, ML	1
Singh, A	1
Horváti, K	1
Bacsa, B	1
Kiss, E	1
Gyulai, G	1
Fodor, K	1
Balka, G	1
Rusvai, M	1
Szabó, E	1
Hudecz, F	1
Bősze, S	1
Beamer, G	1
Major, S	1
Das, B	1
Campos-Neto, A	1
Pienaar, E	1
Cilfone, NA	1
Lin, PL	3
Mattila, JT	1
Butler, JR	1
Flynn, JL	5
Kirschner, DE	1
Linderman, JJ	1
Manina, G	1
Dhar, N	1
McKinney, JD	1
ten Kate, MT	2
van Soolingen, D	2
Aarnoutse, R	1
Boeree, MJ	2
Bakker-Woudenberg, IA	2
de Steenwinkel, JE	2
Garg, T	1
Rath, G	1
Goyal, AK	1
Rodrigues, RF	1
Zárate-Bladés, CR	1
Rios, WM	1
Soares, LS	1
Souza, PR	1
Brandão, IT	1
Masson, AP	1
Arnoldi, FG	1
Ramos, SG	1
Letourneur, F	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Double-Blind, Randomized, Placebo-Controlled Phase II Clinical Trial to Investigate the Safety, Tolerability, and Immunogenicity of the Novel Antituberculous Vaccine RUTI® Following One Month of Isoniazid Treatment in Subjects With Latent Tuberculosis Inf[NCT01136161]	Phase 2	95 participants (Actual)	Interventional	2010-06-30	Completed
Study of Latent Tuberculosis Infection (LTBI) by High Resolution Scanner[NCT00904956]		12 participants (Anticipated)	Observational	2009-11-30	Recruiting
Double-Blind, Randomized, Placebo-Controlled Phase I Study, to Study the Tolerability and Immunogenicity of 4 RUTI Antituberculous Vaccine Different Doses (5, 25, 100 y 200µg of FCMtb) in Healthy Volunteers[NCT00546273]	Phase 1	24 participants (Actual)	Interventional	2007-04-30	Completed
A Phase Ib Safety and Immunogenicity Clinical Trial of Heterologous Prime-boost Immunisation With ChAd3-EBO Z and MVA-EBO Z in Healthy Senegalese Adult Volunteers Aged 18-50 Years.[NCT02485912]	Phase 1	40 participants (Actual)	Interventional	2015-07-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

haematological and biochemical laboratory tests (NCT00546273)
Timeframe: at protocol defined timepoints: days 0, 7, 21, 28, 35, 56, 112 & 156

Safety and Tolerability of Administration of ChAd3-EBO Z and MVA-EBO Z 7 Days Later. This Will be Done by Recording the Number of Participants Who Experience Adverse Events and the Severity of Any Adverse Events.

Intervention	number of abnormalities (Number)
RUTI 5 Micrograms of FCMtb	0
RUTI 25 Micrograms of FCMtb	0
RUTI 100 Micrograms of FCMtb	0
RUTI 200 Micrograms of FCMtb	0
Placebo	0

"The specific endpoints for safety and reactogenicity will be actively and passively collected data on adverse events.~The following parameters will be assessed for both groups:~Occurrence of solicited local reactogenicity signs and symptoms for 7 days following the vaccination~Occurrence of solicited systemic reactogenicity signs and symptoms for 7 days following the vaccination~Occurrence of unsolicited adverse events for 28 days following the vaccination~Change from baseline for safety laboratory measures~Occurrence of serious adverse events during the whole study duration" (NCT02485912)
Timeframe: 26 weeks

To Assess the Immunogenicity Generated by Heterologous Prime-boost Immunisation With Monovalent ChAd3-EBO Z (2.5 x 1010 vp - 3.7 x 1010vp) and MVA-EBO Z (1.0 x 108 Pfu) in Healthy Senegalese Volunteers Aged 18-50 Years

Intervention	participants (Number)
Group 1	20
Group 2	20

"Ebolavirus specific immunogenicity will be assessed by a variety of immunological assays. The primary immunogenicity outcome measures are ELISA and neutralization antigen-specific assays for antibody responses and intracellular cytokine staining (ICS) assay for T cell responses.~Exploratory outcome measures will include ex-vivo ELISPOT, plasma blast assays and flow cytometry performed with research samples collected at different study timepoints as well as other immunogenicity assays throughout the study. An evaluation of genetic factors associated with immune responses may be performed as exploratory evaluation. Vaccine-induced mRNA expression profiles during 1 week after vaccination may also be performed as an exploratory evaluation." (NCT02485912)
Timeframe: 26 weeks

Article	Year
Treatment of tuberculosis and optimal dosing schedules. Thorax, 2011, Volume: 66, Issue:11 Topics: AIDS-Related Opportunistic Infections; Animals; Antitubercular Agents; Child; Disease Models, Animal	2011
A fresh look at the mechanism of isoniazid-induced hepatotoxicity. Clinical pharmacology and therapeutics, 2011, Volume: 89, Issue:6 Topics: Animals; Chemical and Drug Induced Liver Injury; Disease Models, Animal; Humans; Isoniazid; Risk Fac	2011
Latent tuberculosis: models, mechanisms, and novel prospects for eradication. Seminars in pediatric infectious diseases, 2002, Volume: 13, Issue:4 Topics: Animals; Antitubercular Agents; BCG Vaccine; Culture Media; Disease Models, Animal; Genes, Bacterial	2002
[Trends in tuberculosis treatment duration]. Presse medicale (Paris, France : 1983), 2006, Volume: 35, Issue:11 Pt 2 Topics: Animals; Antibiotics, Antitubercular; Antitubercular Agents; Disease Models, Animal; Drug Resistance	2006
Short-course chemoprophylaxis for tuberculosis. Clinics in chest medicine, 1997, Volume: 18, Issue:1 Topics: Animals; Anti-Bacterial Agents; Antibiotic Prophylaxis; Antitubercular Agents; Chronic Disease; Clin	1997
[Iatrogenic lupus: present status of the problem. II. Physiopathology of induced lupus]. La Nouvelle presse medicale, 1972, Dec-09, Volume: 1, Issue:44 Topics: Animals; Antibodies, Antinuclear; Disease Models, Animal; DNA, Viral; Drug-Related Side Effects and	1972
[Complex biological systems as experimental and prenatal toxicology models]. Annali dell'Istituto superiore di sanita, 1997, Volume: 33, Issue:4 Topics: Abnormalities, Drug-Induced; Animals; Animals, Genetically Modified; Caenorhabditis elegans; Cells,	1997

Article	Year
Efficacy of quinoxaline-2-carboxylate 1,4-di-N-oxide derivatives in experimental tuberculosis. Antimicrobial agents and chemotherapy, 2008, Volume: 52, Issue:9 Topics: Animals; Antitubercular Agents; Cyclic N-Oxides; Disease Models, Animal; Drug Resistance, Bacterial;	2008
Bioactive pyridine-N-oxide disulfides from Allium stipitatum. Journal of natural products, 2009, Mar-27, Volume: 72, Issue:3 Topics: 2,2'-Dipyridyl; Alkaloids; Allium; Animals; Anti-Bacterial Agents; Antineoplastic Agents, Phytogenic	2009
Fast standardized therapeutic-efficacy assay for drug discovery against tuberculosis. Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:5 Topics: Acetamides; Animals; Antitubercular Agents; Aza Compounds; Disease Models, Animal; Drug Discovery; E	2010
Identification of SQ609 as a lead compound from a library of dipiperidines. Bioorganic & medicinal chemistry letters, 2011, Sep-15, Volume: 21, Issue:18 Topics: Adamantane; Animals; Antitubercular Agents; Disease Models, Animal; Dose-Response Relationship, Drug	2011
Design, synthesis and evaluation of novel molecules with a diphenyl ether nucleus as potential antitubercular agents. Bioorganic & medicinal chemistry letters, 2012, Jan-15, Volume: 22, Issue:2 Topics: Amines; Animals; Antitubercular Agents; Disease Models, Animal; Dose-Response Relationship, Drug; Fe	2012
Thiazolopyridine ureas as novel antitubercular agents acting through inhibition of DNA Gyrase B. Journal of medicinal chemistry, 2013, Nov-14, Volume: 56, Issue:21 Topics: Animals; Antitubercular Agents; Disease Models, Animal; DNA Gyrase; Dose-Response Relationship, Drug	2013
Thiazolopyridone ureas as DNA gyrase B inhibitors: optimization of antitubercular activity and efficacy. Bioorganic & medicinal chemistry letters, 2014, Feb-01, Volume: 24, Issue:3 Topics: Administration, Oral; Animals; Antitubercular Agents; Disease Models, Animal; Inhibitory Concentrati	2014
Lead optimization of 1,4-azaindoles as antimycobacterial agents. Journal of medicinal chemistry, 2014, Jul-10, Volume: 57, Issue:13 Topics: Alcohol Oxidoreductases; Animals; Antitubercular Agents; Bacterial Proteins; Cyclic Nucleotide Phosp	2014
Synthesis of 3-azabicyclo[3.2.2]nonanes and their antiprotozoal activities. Bioorganic & medicinal chemistry letters, 2015, Apr-01, Volume: 25, Issue:7 Topics: Administration, Oral; Animals; Antiprotozoal Agents; Azabicyclo Compounds; Disease Models, Animal; D	2015
Indole-2-carboxamide-based MmpL3 Inhibitors Show Exceptional Antitubercular Activity in an Animal Model of Tuberculosis Infection. Journal of medicinal chemistry, 2016, 07-14, Volume: 59, Issue:13 Topics: Animals; Antitubercular Agents; Bacterial Proteins; Disease Models, Animal; Drug Design; Female; Hum	2016
Pyrazolo[1,5-a]pyridine-3-carboxamide hybrids: Design, synthesis and evaluation of anti-tubercular activity. European journal of medicinal chemistry, 2017, Jan-05, Volume: 125 Topics: Animals; Antitubercular Agents; Cell Death; Disease Models, Animal; Dose-Response Relationship, Drug	2017
Discovery of new chemical entities as potential leads against Mycobacterium tuberculosis. Bioorganic & medicinal chemistry letters, 2016, 12-15, Volume: 26, Issue:24 Topics: Administration, Oral; Animals; Antitubercular Agents; Biological Availability; Chlorocebus aethiops;	2016
In vivo potent BM635 analogue with improved drug-like properties. European journal of medicinal chemistry, 2018, Feb-10, Volume: 145 Topics: Animals; Antitubercular Agents; Cell Proliferation; Cell Survival; Disease Models, Animal; Dose-Resp	2018
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. Proceedings of the National Academy of Sciences of the United States of America, 2020, 12-08, Volume: 117, Issue:49 Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Dr	2020
Nitroimidazopyrazinones with Oral Activity against Tuberculosis and Chagas Disease in Mouse Models of Infection. Journal of medicinal chemistry, 2022, 10-13, Volume: 65, Issue:19 Topics: Animals; Chagas Disease; Disease Models, Animal; Mice; Mycobacterium tuberculosis; Nitroimidazoles;	2022
Instant hydrogelation encapsulates drugs onto implants intraoperatively against osteoarticular tuberculosis. Journal of materials chemistry. B, 2021, 10-06, Volume: 9, Issue:38 Topics: Animals; Antitubercular Agents; Biocompatible Materials; Calcium Phosphates; Cell Line; Cell Surviva	2021
Treatment of spinal tuberculosis in rabbits using bovine serum albumin nanoparticles loaded with isoniazid and rifampicin. Neurological research, 2022, Volume: 44, Issue:3 Topics: Animals; Antibiotics, Antitubercular; Delayed-Action Preparations; Disease Models, Animal; Isoniazid	2022
Novel Regimens of Bedaquiline-Pyrazinamide Combined with Moxifloxacin, Rifabutin, Delamanid and/or OPC-167832 in Murine Tuberculosis Models. Antimicrobial agents and chemotherapy, 2022, 04-19, Volume: 66, Issue:4 Topics: Animals; Antibiotics, Antitubercular; Antitubercular Agents; Diarylquinolines; Disease Models, Anima	2022
Superior Efficacy of a TBI-166, Bedaquiline, and Pyrazinamide Combination Regimen in a Murine Model of Tuberculosis. Antimicrobial agents and chemotherapy, 2022, 09-20, Volume: 66, Issue:9 Topics: Animals; Antitubercular Agents; Clofazimine; Diarylquinolines; Disease Models, Animal; Isoniazid; Li	2022
Dimethyl fumarate eliminates differentially culturable Frontiers in cellular and infection microbiology, 2022, Volume: 12 Topics: Animals; Antitubercular Agents; Dimethyl Fumarate; Disease Models, Animal; Humans; Isoniazid; Mice;	2022
Results of a pilot study of isoniazid in patients with erythropoietic protoporphyria. Molecular genetics and metabolism, 2019, Volume: 128, Issue:3 Topics: 5-Aminolevulinate Synthetase; Anemia, Sideroblastic; Animals; Disease Models, Animal; Female; Humans	2019
Polymeric nanobiotics as a novel treatment for mycobacterial infections. Journal of controlled release : official journal of the Controlled Release Society, 2019, 11-28, Volume: 314 Topics: Animals; Antitubercular Agents; Clofazimine; Delayed-Action Preparations; Disease Models, Animal; Dr	2019
Adjunctive Immunotherapeutic Efficacy of N-Formylated Internal Peptide of Mycobacterial Glutamine Synthetase in Mouse Model of Tuberculosis. Protein and peptide letters, 2020, Volume: 27, Issue:3 Topics: Animals; Bacterial Load; Bacterial Proteins; Disease Models, Animal; Drug Therapy, Combination; Fema	2020
Protective effect of pyrrolidine dithiocarbamate on isoniazid/rifampicin‑induced liver injury in rats. Molecular medicine reports, 2020, Volume: 21, Issue:1 Topics: Animals; Antioxidants; ATP Binding Cassette Transporter, Subfamily B, Member 11; Chemical and Drug I	2020
Inhalable locust bean gum microparticles co-associating isoniazid and rifabutin: Therapeutic assessment in a murine model of tuberculosis infection. European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 2020, Volume: 147 Topics: Administration, Oral; Animals; Antitubercular Agents; Disease Models, Animal; Drug Combinations; Gal	2020
Nonclinical evaluation of IQG-607, an anti-tuberculosis candidate with potential use in combination drug therapy. Regulatory toxicology and pharmacology : RTP, 2020, Volume: 111 Topics: Animals; Anti-Bacterial Agents; Chromosome Aberrations; Cytochrome P-450 Enzyme System; Disease Mode	2020
Structural Changes in the Lungs and Liver of Mice with Experimental Tuberculosis Treated with Liposome-Encapsulated Dextrazide. Bulletin of experimental biology and medicine, 2020, Volume: 168, Issue:5 Topics: Animals; Dextrans; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Rou	2020
Efficacy of Inhalations of Antituberculous Compositions with Different Length of Experimental Therapy Course in Mice. Bulletin of experimental biology and medicine, 2020, Volume: 168, Issue:6 Topics: Administration, Inhalation; Animals; Antitubercular Agents; Dextrans; Disease Models, Animal; Drug A	2020
Intestinal microbiota disruption limits the isoniazid mediated clearance of Mycobacterium tuberculosis in mice. European journal of immunology, 2020, Volume: 50, Issue:12 Topics: Animals; CD4-Positive T-Lymphocytes; Disease Models, Animal; Dysbiosis; Female; Gastrointestinal Mic	2020
[6]-Gingerol exhibits potent anti-mycobacterial and immunomodulatory activity against tuberculosis. International immunopharmacology, 2020, Volume: 87 Topics: Animals; Anti-Bacterial Agents; Bacterial Load; Catechols; Chemotherapy, Adjuvant; Disease Models, A	2020
The aroylhydrazone INHHQ prevents memory impairment induced by Alzheimer's-linked amyloid-β oligomers in mice. Behavioural pharmacology, 2020, Volume: 31, Issue:8 Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Brain; Disease Mo	2020
Lipid peroxidation aggravates anti-tuberculosis drug-induced liver injury: Evidence of ferroptosis induction. Biochemical and biophysical research communications, 2020, 12-17, Volume: 533, Issue:4 Topics: Animals; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Disease Models, Animal; Drug	2020
Neuroprotective effect of chrysin on isoniazid-induced neurotoxicity via suppression of oxidative stress, inflammation and apoptosis in rats. Neurotoxicology, 2020, Volume: 81 Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Apoptosis; Apoptosis Regulatory Proteins; Cerebral	2020
Ameliorative potential of Adhatoda vasica against anti-tubercular drugs induced hepatic impairments in female Wistar rats in relation to oxidative stress and xeno-metabolism. Journal of ethnopharmacology, 2021, Apr-24, Volume: 270 Topics: Alkaloids; Animals; Antitubercular Agents; Arylamine N-Acetyltransferase; Chemical and Drug Induced	2021
Biofilm formation in the lung contributes to virulence and drug tolerance of Mycobacterium tuberculosis. Nature communications, 2021, 03-11, Volume: 12, Issue:1 Topics: Animals; Biofilms; Cellulase; Cellulose; Disease Models, Animal; Drug Resistance, Multiple, Bacteria	2021
Therapeutic effect of an anti-tuberculosis agent, isoniazid, and its nano-isoform in ulcerative colitis. International immunopharmacology, 2021, Volume: 96 Topics: Animals; Anti-Inflammatory Agents; Antitubercular Agents; Colitis, Ulcerative; Dextran Sulfate; Dise	2021
Effect of niacin supplementation on nausea-like behaviour in an isoniazid-induced mouse model of pellagra. The British journal of nutrition, 2022, 04-14, Volume: 127, Issue:7 Topics: Animals; Dietary Supplements; Disease Models, Animal; Isoniazid; Mice; Nausea; Niacin; Pellagra; Pic	2022
Case Study 10: A Case to Investigate Acetyl Transferase Kinetics. Methods in molecular biology (Clifton, N.J.), 2021, Volume: 2342 Topics: Acetylation; Acetyltransferases; Animals; Clinical Trials as Topic; Disease Models, Animal; Genotype	2021
Metformin Adjunctive Therapy Does Not Improve the Sterilizing Activity of the First-Line Antitubercular Regimen in Mice. Antimicrobial agents and chemotherapy, 2017, Volume: 61, Issue:8 Topics: Animals; Antitubercular Agents; Bacterial Load; Disease Models, Animal; Drug Synergism; Drug Therapy	2017
Assessment of treatment response by colony forming units, time to culture positivity and the molecular bacterial load assay compared in a mouse tuberculosis model. Tuberculosis (Edinburgh, Scotland), 2017, Volume: 105 Topics: Animals; Antitubercular Agents; Bacterial Load; Colony Count, Microbial; Disease Models, Animal; DNA	2017
Assessment of Bactericidal Drug Activity and Treatment Outcome in a Mouse Tuberculosis Model Using a Clinical Beijing Strain. Antimicrobial agents and chemotherapy, 2017, Volume: 61, Issue:10 Topics: Animals; Antitubercular Agents; Disease Models, Animal; Drug Therapy, Combination; Ethambutol; Femal	2017
NOS2-deficient mice with hypoxic necrotizing lung lesions predict outcomes of tuberculosis chemotherapy in humans. Scientific reports, 2017, 08-18, Volume: 7, Issue:1 Topics: Animals; Antitubercular Agents; Disease Models, Animal; Fibrosis; Foam Cells; Humans; Hypoxia; Isoni	2017
Optimal doses of rifampicin in the standard drug regimen to shorten tuberculosis treatment duration and reduce relapse by eradicating persistent bacteria. The Journal of antimicrobial chemotherapy, 2018, 03-01, Volume: 73, Issue:3 Topics: Animals; Antitubercular Agents; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Thera	2018
Vitamin C Potentiates the Killing of Mycobacterium tuberculosis by the First-Line Tuberculosis Drugs Isoniazid and Rifampin in Mice. Antimicrobial agents and chemotherapy, 2018, Volume: 62, Issue:3 Topics: Animals; Antitubercular Agents; Ascorbic Acid; Disease Models, Animal; Drug Resistance, Bacterial; D	2018
Moxifloxacin Replacement in Contemporary Tuberculosis Drug Regimens Is Ineffective against Persistent Mycobacterium tuberculosis in the Cornell Mouse Model. Antimicrobial agents and chemotherapy, 2018, Volume: 62, Issue:7 Topics: Animals; Antitubercular Agents; Disease Models, Animal; Drug Therapy, Combination; Ethambutol; Femal	2018
GM-CSF targeted immunomodulation affects host response to M. tuberculosis infection. Scientific reports, 2018, 06-05, Volume: 8, Issue:1 Topics: Animals; Antibodies, Neutralizing; Antitubercular Agents; Cattle; Disease Models, Animal; Granulocyt	2018
Efficacy and Improved Resistance Potential of a Cofactor-Independent InhA Inhibitor of Mycobacterium tuberculosis in the C3HeB/FeJ Mouse Model. Antimicrobial agents and chemotherapy, 2019, Volume: 63, Issue:4 Topics: Animals; Antitubercular Agents; Aza Compounds; Bacterial Load; Boron Compounds; Disease Models, Anim	2019
Intestinal dysbiosis compromises alveolar macrophage immunity to Mycobacterium tuberculosis. Mucosal immunology, 2019, Volume: 12, Issue:3 Topics: Animals; Antibiotics, Antitubercular; Disease Models, Animal; Drug-Related Side Effects and Adverse	2019
Are preconceptional stressful experiences crucial elements for the aetiology of autism spectrum disorder? Insights from an animal model. Neuropharmacology, 2019, Volume: 157 Topics: Animals; Autism Spectrum Disorder; Behavior, Animal; Brain-Derived Neurotrophic Factor; Disease Mode	2019
Evaluation of antihepatotoxic potential of Solanum xanthocarpum fruit extract against antitubercular drugs induced hepatopathy in experimental rodents. Asian Pacific journal of tropical biomedicine, 2012, Volume: 2, Issue:6 Topics: Animals; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Disease Models, Animal; Fema	2012
The polyphosphate kinase gene ppk2 is required for Mycobacterium tuberculosis inorganic polyphosphate regulation and virulence. mBio, 2013, May-21, Volume: 4, Issue:3 Topics: Animals; Antitubercular Agents; Bacterial Load; Disease Models, Animal; Female; Gene Deletion; Isoni	2013
Immunotherapeutic efficacy of recombinant Mycobacterium smegmatis expressing Ag85B-ESAT6 fusion protein against persistent tuberculosis infection in mice. Human vaccines & immunotherapeutics, 2014, Volume: 10, Issue:1 Topics: Acyltransferases; Animals; Antigens, Bacterial; Antitubercular Agents; Bacteria; Bacterial Load; Bac	2014
Isoniazid-induced liver injury and immune response in mice. Journal of immunotoxicology, 2014, Volume: 11, Issue:4 Topics: Adaptive Immunity; Adaptor Proteins, Signal Transducing; Animals; Antitubercular Agents; Chemical an	2014
Hepatoprotective potential of Cassia auriculata roots on ethanol and antitubercular drug-induced hepatotoxicity in experimental models. Pharmaceutical biology, 2014, Volume: 52, Issue:3 Topics: Animals; Antioxidants; Antitubercular Agents; Cassia; Chemical and Drug Induced Liver Injury; Diseas	2014
Reduced emergence of isoniazid resistance with concurrent use of thioridazine against acute murine tuberculosis. Antimicrobial agents and chemotherapy, 2014, Volume: 58, Issue:7 Topics: Animals; Antipsychotic Agents; Antitubercular Agents; Disease Models, Animal; Drug Repositioning; Dr	2014
Simvastatin increases the in vivo activity of the first-line tuberculosis regimen. The Journal of antimicrobial chemotherapy, 2014, Volume: 69, Issue:9 Topics: Animals; Antitubercular Agents; Bacterial Load; Cell Line; Colony Count, Microbial; Disease Models,	2014
Sterilizing activity of thioridazine in combination with the first-line regimen against acute murine tuberculosis. Antimicrobial agents and chemotherapy, 2014, Volume: 58, Issue:9 Topics: Animals; Antitubercular Agents; Disease Models, Animal; Drug Therapy, Combination; Female; Isoniazid	2014
PA-824 is as effective as isoniazid against latent tuberculosis infection in C3HeB/FeJ mice. International journal of antimicrobial agents, 2014, Volume: 44, Issue:6 Topics: Animals; Antitubercular Agents; Disease Models, Animal; Female; Isoniazid; Latent Tuberculosis; Lung	2014
Chemotherapeutic efficacy of thioridazine as an adjunct drug in a murine model of latent tuberculosis. Tuberculosis (Edinburgh, Scotland), 2014, Volume: 94, Issue:6 Topics: Animals; Antitubercular Agents; Colony Count, Microbial; Disease Models, Animal; Dose-Response Relat	2014
Nanoparticle encapsulated lipopeptide conjugate of antitubercular drug isoniazid: in vitro intracellular activity and in vivo efficacy in a Guinea pig model of tuberculosis. Bioconjugate chemistry, 2014, Dec-17, Volume: 25, Issue:12 Topics: Animals; Antitubercular Agents; Disease Models, Animal; Drug Carriers; Female; Guinea Pigs; Humans;	2014
Bone marrow mesenchymal stem cells provide an antibiotic-protective niche for persistent viable Mycobacterium tuberculosis that survive antibiotic treatment. The American journal of pathology, 2014, Volume: 184, Issue:12 Topics: Adapalene; Animals; Anti-Bacterial Agents; Antitubercular Agents; Bone Marrow; Bone Marrow Cells; Di	2014
A computational tool integrating host immunity with antibiotic dynamics to study tuberculosis treatment. Journal of theoretical biology, 2015, Feb-21, Volume: 367 Topics: Animals; Anti-Bacterial Agents; Antitubercular Agents; Calibration; Computer Simulation; Disease Mod	2015
Stress and host immunity amplify Mycobacterium tuberculosis phenotypic heterogeneity and induce nongrowing metabolically active forms. Cell host & microbe, 2015, Jan-14, Volume: 17, Issue:1 Topics: Animals; Antitubercular Agents; Disease Models, Animal; Female; Gene Expression Profiling; Host-Path	2015
Enhancement of in vitro activity of tuberculosis drugs by addition of thioridazine is not reflected by improved in vivo therapeutic efficacy. Tuberculosis (Edinburgh, Scotland), 2014, Volume: 94, Issue:6 Topics: Animals; Antitubercular Agents; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Combi	2014
Inhalable chitosan nanoparticles as antitubercular drug carriers for an effective treatment of tuberculosis. Artificial cells, nanomedicine, and biotechnology, 2016, Volume: 44, Issue:3 Topics: Administration, Inhalation; Animals; Antibiotics, Antitubercular; Chitosan; Disease Models, Animal;	2016
Synergy of chemotherapy and immunotherapy revealed by a genome-scale analysis of murine tuberculosis. The Journal of antimicrobial chemotherapy, 2015, Volume: 70, Issue:6 Topics: Animals; Antitubercular Agents; Combined Modality Therapy; Disease Models, Animal; Drug Therapy; Gen	2015
Therapeutic efficacy of liposomes containing 4-(5-pentadecyl-1,3,4-oxadiazol-2-yl)pyridine in a murine model of progressive pulmonary tuberculosis. Pulmonary pharmacology & therapeutics, 2015, Volume: 32 Topics: Animals; Antitubercular Agents; Cholesterol; Disease Models, Animal; Isoniazid; Liposomes; Male; Mic	2015
pH-Responsive Isoniazid-Loaded Nanoparticles Markedly Improve Tuberculosis Treatment in Mice. Small (Weinheim an der Bergstrasse, Germany), 2015, Volume: 11, Issue:38 Topics: Aldehydes; Animals; CHO Cells; Cricetinae; Cricetulus; Disease Models, Animal; Female; Humans; Hydro	2015
Cell division inhibitors with efficacy equivalent to isoniazid in the acute murine Mycobacterium tuberculosis infection model. The Journal of antimicrobial chemotherapy, 2015, Volume: 70, Issue:11 Topics: Administration, Oral; Animals; Antitubercular Agents; Bacterial Proteins; Benzimidazoles; Cell Divis	2015
Roflumilast, a Type 4 Phosphodiesterase Inhibitor, Shows Promising Adjunctive, Host-Directed Therapeutic Activity in a Mouse Model of Tuberculosis. Antimicrobial agents and chemotherapy, 2015, Volume: 59, Issue:12 Topics: Aminopyridines; Animals; Antitubercular Agents; Benzamides; Cyclopropanes; Disease Models, Animal; F	2015
The Combination of Anti-CTLA-4 and PD1-/- Mice Unmasks the Potential of Isoniazid and Nevirapine To Cause Liver Injury. Chemical research in toxicology, 2015, Dec-21, Volume: 28, Issue:12 Topics: Animals; Antibodies, Monoclonal; Chemical and Drug Induced Liver Injury; Disease Models, Animal; Fem	2015
MicroRNA-122 is involved in oxidative stress in isoniazid-induced liver injury in mice. Genetics and molecular research : GMR, 2015, Oct-27, Volume: 14, Issue:4 Topics: Animals; Chemical and Drug Induced Liver Injury; Disease Models, Animal; Female; Gene Expression; Is	2015
Sterilizing Activity of Pyrazinamide in Combination with First-Line Drugs in a C3HeB/FeJ Mouse Model of Tuberculosis. Antimicrobial agents and chemotherapy, 2016, Volume: 60, Issue:2 Topics: Animals; Antitubercular Agents; Disease Models, Animal; Drug Resistance, Bacterial; Drug Therapy, Co	2016
Clofazimine Contributes Sustained Antimicrobial Activity after Treatment Cessation in a Mouse Model of Tuberculosis Chemotherapy. Antimicrobial agents and chemotherapy, 2016, Volume: 60, Issue:5 Topics: Animals; Antitubercular Agents; Clofazimine; Disease Models, Animal; Drug Combinations; Drug Therapy	2016
Determination of anti-tuberculosis drug concentration and distribution from sustained release microspheres in the vertebrae of a spinal tuberculosis rabbit model. Journal of orthopaedic research : official publication of the Orthopaedic Research Society, 2017, Volume: 35, Issue:1 Topics: Animals; Antitubercular Agents; Disease Models, Animal; Drug Delivery Systems; Durapatite; Female; I	2017
Amelioration of anti-tuberculosis drug induced oxidative stress in kidneys by Spirulina fusiformis in a rat model. Renal failure, 2016, Volume: 38, Issue:7 Topics: Acute Kidney Injury; Animals; Antioxidants; Antitubercular Agents; Creatinine; Disease Models, Anima	2016
Investigation of Elimination Rate, Persistent Subpopulation Removal, and Relapse Rates of Mycobacterium tuberculosis by Using Combinations of First-Line Drugs in a Modified Cornell Mouse Model. Antimicrobial agents and chemotherapy, 2016, Volume: 60, Issue:8 Topics: Animals; Antitubercular Agents; Disease Models, Animal; Drug Combinations; Female; Isoniazid; Mice;	2016
Therapeutic Potential of the Mycobacterium tuberculosis Mycolic Acid Transporter, MmpL3. Antimicrobial agents and chemotherapy, 2016, Volume: 60, Issue:9 Topics: Animals; Antitubercular Agents; Bacterial Load; Bacterial Proteins; Biological Transport; Ciprofloxa	2016
Population pharmacokinetics, optimised design and sample size determination for rifampicin, isoniazid, ethambutol and pyrazinamide in the mouse. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 2016, Oct-10, Volume: 93 Topics: Animals; Antibiotics, Antitubercular; Disease Models, Animal; Ethambutol; Isoniazid; Mice, Inbred C5	2016
Stringent Response Factors PPX1 and PPK2 Play an Important Role in Mycobacterium tuberculosis Metabolism, Biofilm Formation, and Sensitivity to Isoniazid In Vivo. Antimicrobial agents and chemotherapy, 2016, Volume: 60, Issue:11 Topics: Acid Anhydride Hydrolases; Animals; Antitubercular Agents; Biofilms; Citric Acid Cycle; Clofazimine;	2016
Impact of the interaction of R207910 with rifampin on the treatment of tuberculosis studied in the mouse model. Antimicrobial agents and chemotherapy, 2008, Volume: 52, Issue:10 Topics: Animals; Antibiotics, Antitubercular; Antitubercular Agents; Colony Count, Microbial; Diarylquinolin	2008
Enhanced bactericidal activity of rifampin and/or pyrazinamide when combined with PA-824 in a murine model of tuberculosis. Antimicrobial agents and chemotherapy, 2008, Volume: 52, Issue:10 Topics: Animals; Antibiotics, Antitubercular; Antitubercular Agents; Colony Count, Microbial; Disease Models	2008
Isoniazid or moxifloxacin in rifapentine-based regimens for experimental tuberculosis? American journal of respiratory and critical care medicine, 2008, Nov-01, Volume: 178, Issue:9 Topics: Animals; Antibiotics, Antitubercular; Antitubercular Agents; Aza Compounds; Disease Models, Animal;	2008
Protective role of caffeic acid phenethyl ester and erdosteine on activities of purine-catabolizing enzymes and level of nitric oxide in red blood cells of isoniazid-administered rats. Toxicology and industrial health, 2008, Volume: 24, Issue:8 Topics: Adenosine Deaminase; Administration, Oral; Animals; Antioxidants; Antitubercular Agents; Caffeic Aci	2008
[Hixozide, a novel combined antituberculosis preparation]. Antibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic], 2008, Volume: 53, Issue:5-6 Topics: Animals; Antitubercular Agents; Cells, Cultured; Disease Models, Animal; Drug Combinations; Drug Eva	2008
Lung carcinogenesis induced by chronic tuberculosis infection: the experimental model and genetic control. Oncogene, 2009, Apr-30, Volume: 28, Issue:17 Topics: Animals; Antitubercular Agents; Carcinoma, Squamous Cell; Cell Transformation, Neoplastic; Chronic D	2009
Effect of vitamin C on oxidative liver injury due to isoniazid in rats. Pediatrics international : official journal of the Japan Pediatric Society, 2010, Volume: 52, Issue:1 Topics: Animals; Antioxidants; Antitubercular Agents; Ascorbic Acid; Chemical and Drug Induced Liver Injury;	2010
Sterilizing activity of R207910 (TMC207)-containing regimens in the murine model of tuberculosis. American journal of respiratory and critical care medicine, 2009, Sep-15, Volume: 180, Issue:6 Topics: Animals; Antitubercular Agents; Diarylquinolines; Disease Models, Animal; Drug Therapy, Combination;	2009
[Gene expression profile of isoniazid liver-injured rat using cDNA microarray]. Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae, 2009, Volume: 31, Issue:3 Topics: Animals; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Disease Models, Animal; Gene	2009
Use of non-invasive bioluminescent imaging to assess mycobacterial dissemination in mice, treatment with bactericidal drugs and protective immunity. Microbes and infection, 2009, Volume: 11, Issue:14-15 Topics: Animals; Antitubercular Agents; Diagnostic Imaging; Disease Models, Animal; Humans; Isoniazid; Lucif	2009
Protective effects of thiopronin against isoniazid-induced hepatotoxicity in rats. Toxicology, 2009, Oct-29, Volume: 264, Issue:3 Topics: 8-Hydroxy-2'-Deoxyguanosine; Alanine Transaminase; Aniline Compounds; Animals; Aspartate Aminotransf	2009
Experimental ocular tuberculosis in guinea pigs. Archives of ophthalmology (Chicago, Ill. : 1960), 2009, Volume: 127, Issue:9 Topics: Aerosols; Animals; Antitubercular Agents; Disease Models, Animal; DNA, Bacterial; Guinea Pigs; Isoni	2009
A short-term model for preliminary screening of potential anti-tubercular compounds. Scandinavian journal of infectious diseases, 2009, Volume: 41, Issue:11-12 Topics: Animals; Antitubercular Agents; Colony Count, Microbial; Disease Models, Animal; Drug Discovery; Fem	2009
Comparison of the 'Denver regimen' against acute tuberculosis in the mouse and guinea pig. The Journal of antimicrobial chemotherapy, 2010, Volume: 65, Issue:4 Topics: Animals; Antitubercular Agents; Disease Models, Animal; Female; Guinea Pigs; Isoniazid; Lung; Mice;	2010
Evaluation of standard chemotherapy in the guinea pig model of tuberculosis. Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:5 Topics: Animals; Animals, Outbred Strains; Antitubercular Agents; Biomarkers; CD8-Positive T-Lymphocytes; Di	2010
Therapeutic potential of peptide deformylase inhibitors against experimental tuberculosis. The Journal of infection, 2010, Volume: 60, Issue:6 Topics: Amidohydrolases; Analysis of Variance; Animals; Antitubercular Agents; Colony Count, Microbial; Dise	2010
Granuloma encapsulation is a key factor for containing tuberculosis infection in minipigs. PloS one, 2010, Apr-06, Volume: 5, Issue:4 Topics: Animals; Bacterial Vaccines; Disease Models, Animal; Fibrosis; Granuloma; Immunity, Humoral; Isoniaz	2010
Granuloma encapsulation is a key factor for containing tuberculosis infection in minipigs. PloS one, 2010, Apr-06, Volume: 5, Issue:4 Topics: Animals; Bacterial Vaccines; Disease Models, Animal; Fibrosis; Granuloma; Immunity, Humoral; Isoniaz	2010
Granuloma encapsulation is a key factor for containing tuberculosis infection in minipigs. PloS one, 2010, Apr-06, Volume: 5, Issue:4 Topics: Animals; Bacterial Vaccines; Disease Models, Animal; Fibrosis; Granuloma; Immunity, Humoral; Isoniaz	2010
Granuloma encapsulation is a key factor for containing tuberculosis infection in minipigs. PloS one, 2010, Apr-06, Volume: 5, Issue:4 Topics: Animals; Bacterial Vaccines; Disease Models, Animal; Fibrosis; Granuloma; Immunity, Humoral; Isoniaz	2010
Posttreatment reactivation of tuberculosis in mice caused by Mycobacterium tuberculosis disrupted in mce1R. The Journal of infectious diseases, 2010, Sep-01, Volume: 202, Issue:5 Topics: Animals; Antitubercular Agents; Bacterial Proteins; Disease Models, Animal; Female; Humans; Isoniazi	2010
Treatment of tuberculosis with rifamycin-containing regimens in immune-deficient mice. American journal of respiratory and critical care medicine, 2011, May-01, Volume: 183, Issue:9 Topics: Animals; Anti-Inflammatory Agents; Antibiotics, Antitubercular; Antitubercular Agents; Cortisone; Di	2011
Phosphodiesterase 4 inhibition reduces innate immunity and improves isoniazid clearance of Mycobacterium tuberculosis in the lungs of infected mice. PloS one, 2011, Feb-25, Volume: 6, Issue:2 Topics: Animals; Antibiotics, Antitubercular; Bacterial Load; Cyclic Nucleotide Phosphodiesterases, Type 4;	2011
Torticollis in mice intravenously infected with Mycobacterium tuberculosis. Journal of the American Association for Laboratory Animal Science : JAALAS, 2011, Volume: 50, Issue:2 Topics: Animals; Antitubercular Agents; Autopsy; Aza Compounds; Disease Models, Animal; Drug Therapy, Combin	2011
Use of whole genome sequencing to estimate the mutation rate of Mycobacterium tuberculosis during latent infection. Nature genetics, 2011, Volume: 43, Issue:5 Topics: Animals; Antitubercular Agents; Base Sequence; Disease Models, Animal; DNA, Bacterial; Drug Resistan	2011
T cell monitoring of chemotherapy in experimental rat tuberculosis. Antimicrobial agents and chemotherapy, 2011, Volume: 55, Issue:8 Topics: Animals; Antibiotics, Antitubercular; Antigens, Bacterial; Antitubercular Agents; Bacterial Proteins	2011
Pharmacokinetic evaluation of the penetration of antituberculosis agents in rabbit pulmonary lesions. Antimicrobial agents and chemotherapy, 2012, Volume: 56, Issue:1 Topics: Animals; Antitubercular Agents; Aza Compounds; Biological Availability; Disease Models, Animal; Drug	2012
Importance of confirming data on the in vivo efficacy of novel antibacterial drug regimens against various strains of Mycobacterium tuberculosis. Antimicrobial agents and chemotherapy, 2012, Volume: 56, Issue:2 Topics: Animals; Antitubercular Agents; Disease Models, Animal; Drug Therapy, Combination; Female; Humans; I	2012
Sedative, antiepileptic and antipsychotic effects of Viscum album L. (Loranthaceae) in mice and rats. Journal of ethnopharmacology, 2012, Jun-14, Volume: 141, Issue:3 Topics: Animals; Anticonvulsants; Antipsychotic Agents; Apomorphine; Catalepsy; Disease Models, Animal; Epil	2012
Janus-faced liposomes enhance antimicrobial innate immune response in Mycobacterium tuberculosis infection. Proceedings of the National Academy of Sciences of the United States of America, 2012, May-22, Volume: 109, Issue:21 Topics: Adult; Animals; Antitubercular Agents; Apoptosis; Bronchoalveolar Lavage Fluid; Calcium; Cell Line,	2012
Dose-ranging comparison of rifampin and rifapentine in two pathologically distinct murine models of tuberculosis. Antimicrobial agents and chemotherapy, 2012, Volume: 56, Issue:8 Topics: Animals; Antibiotics, Antitubercular; Antitubercular Agents; Disease Models, Animal; Drug Administra	2012
Infection dynamics and response to chemotherapy in a rabbit model of tuberculosis using [¹⁸F]2-fluoro-deoxy-D-glucose positron emission tomography and computed tomography. Antimicrobial agents and chemotherapy, 2012, Volume: 56, Issue:8 Topics: Animals; Antitubercular Agents; Bacterial Load; Disease Models, Animal; Fluorodeoxyglucose F18; Gran	2012
In vitro and in vivo activity of clofazimine against Mycobacterium tuberculosis persisters. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2012, Volume: 16, Issue:8 Topics: Animals; Antitubercular Agents; Aza Compounds; Chronic Disease; Clofazimine; Disease Models, Animal;	2012
Activity of IQG-607, a new orally active compound, in a murine model of Mycobacterium tuberculosis infection. International journal of antimicrobial agents, 2012, Volume: 40, Issue:2 Topics: Animals; Antitubercular Agents; Bacterial Load; Disease Models, Animal; Drug Evaluation, Preclinical	2012
Pharmacokinetic/pharmacodynamic parameters and the choice of high-dosage rifamycins. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2012, Volume: 16, Issue:9 Topics: Acetylation; Animals; Antitubercular Agents; Area Under Curve; Disease Models, Animal; Dose-Response	2012
Consequences of noncompliance for therapy efficacy and emergence of resistance in murine tuberculosis caused by the Beijing genotype of Mycobacterium tuberculosis. Antimicrobial agents and chemotherapy, 2012, Volume: 56, Issue:9 Topics: Animals; Antitubercular Agents; Bacterial Typing Techniques; Disease Models, Animal; Drug Administra	2012
Metronidazole prevents reactivation of latent Mycobacterium tuberculosis infection in macaques. Proceedings of the National Academy of Sciences of the United States of America, 2012, Aug-28, Volume: 109, Issue:35 Topics: Animals; Antiprotozoal Agents; Antitubercular Agents; Disease Models, Animal; Dose-Response Relation	2012
Therapeutic immunization against Mycobacterium tuberculosis is an effective adjunct to antibiotic treatment. The Journal of infectious diseases, 2013, Apr-15, Volume: 207, Issue:8 Topics: Adjuvants, Immunologic; Animals; Antigens, Bacterial; Antitubercular Agents; Bacterial Proteins; Che	2013
Modeling early bactericidal activity in murine tuberculosis provides insights into the activity of isoniazid and pyrazinamide. Proceedings of the National Academy of Sciences of the United States of America, 2012, Sep-11, Volume: 109, Issue:37 Topics: Analysis of Variance; Animals; Antitubercular Agents; Colony Count, Microbial; Disease Models, Anima	2012
Antiepileptic potential of ursolic acid stearoyl glucoside by GABA receptor stimulation. CNS neuroscience & therapeutics, 2012, Volume: 18, Issue:9 Topics: Animals; Anticonvulsants; Convulsants; Diazepam; Disease Models, Animal; Dose-Response Relationship,	2012
Inhibition of Mycobacterium tuberculosis glutamine synthetase as a novel antibiotic strategy against tuberculosis: demonstration of efficacy in vivo. Infection and immunity, 2003, Volume: 71, Issue:1 Topics: Animals; Anti-Bacterial Agents; Antitubercular Agents; Colony Count, Microbial; Disease Models, Anim	2003
[Preliminary study on isoniazid-epiroprim combination in a tuberculosis murine model]. Bulletin de la Societe de pathologie exotique (1990), 2002, Volume: 95, Issue:4 Topics: Animals; Antitubercular Agents; Disease Models, Animal; Drug Evaluation, Preclinical; Drug Therapy,	2002
Impact of iron loading on the activity of isoniazid or ethambutol in the treatment of murine tuberculosis. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2003, Volume: 7, Issue:6 Topics: Animals; Antitubercular Agents; Disease Models, Animal; Drug Interactions; Ethambutol; Female; Iron;	2003
Catalase-peroxidase activity has no influence on virulence in a murine model of tuberculosis. Tuberculosis (Edinburgh, Scotland), 2003, Volume: 83, Issue:6 Topics: Animals; Antitubercular Agents; Bacterial Proteins; Disease Models, Animal; Drug Resistance, Bacteri	2003
Liposome-based antitubercular drug therapy in a guinea pig model of tuberculosis. International journal of antimicrobial agents, 2004, Volume: 23, Issue:4 Topics: Animals; Antitubercular Agents; Disease Models, Animal; Guinea Pigs; Humans; Isoniazid; Liposomes; M	2004
[Experimental evidence for Mycobacterium tuberculosis persistence in M. tuberculosis-infected H37RV mice in the treatment with 3 first-line drugs (rifampicin, isoniazid, pyrazinamide)]. Problemy tuberkuleza i boleznei legkikh, 2004, Issue:3 Topics: Animals; Antibiotics, Antitubercular; Antitubercular Agents; Disease Models, Animal; DNA, Bacterial;	2004
Dormancy phenotype displayed by extracellular Mycobacterium tuberculosis within artificial granulomas in mice. The Journal of experimental medicine, 2004, Sep-06, Volume: 200, Issue:5 Topics: Animals; Cell Survival; Disease Models, Animal; Female; Gene Expression Regulation, Bacterial; Granu	2004
Role of human neutrophil peptide-1 as a possible adjunct to antituberculosis chemotherapy. The Journal of infectious diseases, 2004, Oct-15, Volume: 190, Issue:8 Topics: alpha-Defensins; Animals; Anti-Infective Agents; Antitubercular Agents; Cell Line; Disease Models, A	2004
Acute effect of an extract of Ambrosia paniculata (Willd.) O. E. Schultz (mugwort) in several models of experimental epilepsy. Epilepsy & behavior : E&B, 2004, Volume: 5, Issue:6 Topics: Ambrosia; Analysis of Variance; Animals; Anticonvulsants; Behavior, Animal; Cerebral Cortex; Diazepa	2004
Immunotherapy with fragmented Mycobacterium tuberculosis cells increases the effectiveness of chemotherapy against a chronical infection in a murine model of tuberculosis. Vaccine, 2005, Feb-03, Volume: 23, Issue:11 Topics: Animals; Antibodies, Bacterial; Antitubercular Agents; Colony Count, Microbial; Combined Modality Th	2005
Immunotherapy with fragmented Mycobacterium tuberculosis cells increases the effectiveness of chemotherapy against a chronical infection in a murine model of tuberculosis. Vaccine, 2005, Feb-03, Volume: 23, Issue:11 Topics: Animals; Antibodies, Bacterial; Antitubercular Agents; Colony Count, Microbial; Combined Modality Th	2005
Immunotherapy with fragmented Mycobacterium tuberculosis cells increases the effectiveness of chemotherapy against a chronical infection in a murine model of tuberculosis. Vaccine, 2005, Feb-03, Volume: 23, Issue:11 Topics: Animals; Antibodies, Bacterial; Antitubercular Agents; Colony Count, Microbial; Combined Modality Th	2005
Immunotherapy with fragmented Mycobacterium tuberculosis cells increases the effectiveness of chemotherapy against a chronical infection in a murine model of tuberculosis. Vaccine, 2005, Feb-03, Volume: 23, Issue:11 Topics: Animals; Antibodies, Bacterial; Antitubercular Agents; Colony Count, Microbial; Combined Modality Th	2005
Imipenem for treatment of tuberculosis in mice and humans. Antimicrobial agents and chemotherapy, 2005, Volume: 49, Issue:7 Topics: Animals; Anti-Bacterial Agents; Colony Count, Microbial; Disease Models, Animal; Drug Resistance, Mu	2005
Mitochondrial oxidative stress and permeability transition in isoniazid and rifampicin induced liver injury in mice. Journal of hepatology, 2006, Volume: 45, Issue:1 Topics: Animals; Disease Models, Animal; Fatty Liver; Glutathione; Isoniazid; Liver; Male; Mice; Mice, Inbre	2006
Passive serum therapy with polyclonal antibodies against Mycobacterium tuberculosis protects against post-chemotherapy relapse of tuberculosis infection in SCID mice. Microbes and infection, 2006, Volume: 8, Issue:5 Topics: Animals; Antibodies, Bacterial; Antitubercular Agents; Disease Models, Animal; Female; Humans; Immun	2006
Behavioral and antiepileptic effect of acute administration of the extract of the aquatic plant Echinodorus berteroi (Sprengel) Fassett (upright burhead). Epilepsy & behavior : E&B, 2006, Volume: 9, Issue:1 Topics: Alismataceae; Animals; Central Nervous System; Convulsants; Disease Models, Animal; Dose-Response Re	2006
Combination chemotherapy with the nitroimidazopyran PA-824 and first-line drugs in a murine model of tuberculosis. Antimicrobial agents and chemotherapy, 2006, Volume: 50, Issue:8 Topics: Animals; Antibiotics, Antitubercular; Antitubercular Agents; Disease Models, Animal; Drug Therapy, C	2006
[Effect of use of bone marrow cells in therapy for experimental tuberculosis]. Problemy tuberkuleza i boleznei legkikh, 2006, Issue:10 Topics: Animals; Antitubercular Agents; Bone Marrow Transplantation; Combined Modality Therapy; Disease Mode	2006
[Reduced mycobacterial resistance to antituberculous drugs in the experiment and clinic: immediate and long-term results]. Problemy tuberkuleza i boleznei legkikh, 2007, Issue:2 Topics: Adolescent; Adult; Animals; Anti-Bacterial Agents; Antibiotics, Antitubercular; Antitubercular Agent	2007
Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model. PLoS medicine, 2007, Volume: 4, Issue:12 Topics: Animals; Antibiotics, Antitubercular; Antitubercular Agents; Aza Compounds; Colony Count, Microbial;	2007
Behavioral and antiepileptic effects of acute administration of the extract of the plant Cestrum nocturnum Lin (lady of the night). Epilepsy & behavior : E&B, 2008, Volume: 12, Issue:3 Topics: Amphetamine; Animals; Anticonvulsants; Behavior, Animal; Central Nervous System Stimulants; Cestrum;	2008
Isoniazid treatment of Mycobacterium bovis in cattle as a model for human tuberculosis. Tuberculosis (Edinburgh, Scotland), 2008, Volume: 88, Issue:6 Topics: Animals; Antigens, Bacterial; Antitubercular Agents; Cattle; Cattle Diseases; Cytokines; Disease Mod	2008
[Symptomatic therapy in a possible animal model for Huntington's chorea]. Arzneimittel-Forschung, 1981, Volume: 31, Issue:3 Topics: Animals; Bromocriptine; Disease Models, Animal; Glucosamine; Huntington Disease; Isoniazid; Male; Ni	1981
Anticonvulsant effects of PGE2 on electrical, chemical and photomyoclonic animal models of epilepsy. Progress in lipid research, 1981, Volume: 20 Topics: Animals; Anticonvulsants; Brain; Dinoprostone; Disease Models, Animal; Electric Stimulation; gamma-A	1981
The guinea pig as a model for isoniazid-induced reactions. Laboratory animal science, 1980, Volume: 30, Issue:1 Topics: Animals; Aspartate Aminotransferases; Chemical and Drug Induced Liver Injury; Disease Models, Animal	1980
[Changes in the granuloma in the experimental treatment of tuberculosis with a prolonged form of isoniazid]. Problemy tuberkuleza, 1993, Issue:1 Topics: Animals; Chronic Disease; Delayed-Action Preparations; Dextrans; Disease Models, Animal; Drug Combin	1993
A model of isoniazid-induced hepatotoxicity in rabbits. Journal of pharmacological and toxicological methods, 1995, Volume: 34, Issue:2 Topics: Administration, Oral; Analysis of Variance; Animals; Argininosuccinate Lyase; Disease Models, Animal	1995
In vivo inhibition of kynurenine aminotransferase activity by isonicotinic acid hydrazide in rats. Bioscience, biotechnology, and biochemistry, 1996, Volume: 60, Issue:5 Topics: Animals; Antitubercular Agents; Disease Models, Animal; Enzyme Inhibitors; Isoniazid; Lyases; Male;	1996
Prevention of postasphyxia electroretinal dysfunction with a pyridoxal hydrazone. Free radical biology & medicine, 1997, Volume: 22, Issue:1-2 Topics: Animals; Animals, Newborn; Asphyxia Neonatorum; Deferoxamine; Disease Models, Animal; Electroretinog	1997
[Antitubercular activity of lomefloxacin in an experiment]. Antibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic], 1996, Volume: 41, Issue:7-8 Topics: Animals; Anti-Infective Agents; Antitubercular Agents; Disease Models, Animal; Dose-Response Relatio	1996
[Antibacterial effectiveness of long-acting isoniazid in the experiment]. Problemy tuberkuleza, 1997, Issue:2 Topics: Animals; Antitubercular Agents; Cattle; Delayed-Action Preparations; Disease Models, Animal; Isoniaz	1997
A combination of thalidomide plus antibiotics protects rabbits from mycobacterial meningitis-associated death. The Journal of infectious diseases, 1998, Volume: 177, Issue:6 Topics: Animals; Antibiotics, Antitubercular; Disease Models, Animal; Drug Therapy, Combination; Immunosuppr	1998
Increased abundance of GABAA receptor subunit mRNAs in the brain of Long-Evans Cinnamon rats, an animal model of Wilson's disease. Brain research. Molecular brain research, 1999, Jan-08, Volume: 63, Issue:2 Topics: Aging; Analysis of Variance; Animals; Disease Models, Animal; Hepatolenticular Degeneration; Isoniaz	1999
[Examining fibrotic process in lung during treatment of chronic murine tuberculosis with lysosomotropic drug isonaizid]. Problemy tuberkuleza, 1999, Issue:1 Topics: Animals; Antitubercular Agents; Chronic Disease; Disease Models, Animal; Fibrosis; Follow-Up Studies	1999
Chemotherapy of tuberculosis in mice using single implants of isoniazid and pyrazinamide. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 1999, Volume: 3, Issue:6 Topics: Administration, Oral; Analysis of Variance; Animals; Antitubercular Agents; Biocompatible Materials;	1999
Reactivation of latent tuberculosis: variations on the Cornell murine model. Infection and immunity, 1999, Volume: 67, Issue:9 Topics: Animals; Antitubercular Agents; Dexamethasone; Disease Models, Animal; Genetic Variation; Glucocorti	1999
Analysis of rifapentine for preventive therapy in the Cornell mouse model of latent tuberculosis. Antimicrobial agents and chemotherapy, 1999, Volume: 43, Issue:9 Topics: Animals; Antibiotics, Antitubercular; Antitubercular Agents; Colony Count, Microbial; Disease Models	1999
Evaluation of rifapentine in long-term treatment regimens for tuberculosis in mice. Antimicrobial agents and chemotherapy, 1999, Volume: 43, Issue:10 Topics: Animals; Antibiotics, Antitubercular; Antitubercular Agents; Disease Models, Animal; Drug Therapy, C	1999
Durable cure for tuberculosis: rifalazil in combination with isoniazid in a murine model of Mycobacterium tuberculosis infection. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2000, Volume: 30 Suppl 3 Topics: Animals; Antitubercular Agents; Colony Count, Microbial; Dexamethasone; Disease Models, Animal; Drug	2000
Evaluation of rifalazil in a combination treatment regimen as an alternative to isoniazid-rifampin therapy in a mouse tuberculosis model. Antimicrobial agents and chemotherapy, 2000, Volume: 44, Issue:11 Topics: Animals; Antitubercular Agents; Colony-Forming Units Assay; Disease Models, Animal; Drug Therapy, Co	2000
Differential role of dopamine D1 and D2 receptors in isoniazid-induced vacuous chewing movements. Methods and findings in experimental and clinical pharmacology, 2000, Volume: 22, Issue:10 Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Anticonvulsants; Antipsychotic	2000
Chemotherapy of Mycobacterium tuberculosis infections in mice with a combination of isoniazid and rifampicin entrapped in Poly (DL-lactide-co-glycolide) microparticles. The Journal of antimicrobial chemotherapy, 2001, Volume: 47, Issue:6 Topics: Animals; Antibiotics, Antitubercular; Antitubercular Agents; Capsules; Disease Models, Animal; Drug	2001
Animal models of tardive dyskinesia--a review. Indian journal of physiology and pharmacology, 2001, Volume: 45, Issue:2 Topics: Animals; Antipsychotic Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; Free Radicals; gamm	2001
Complete, long-lasting protection against malaria of mice primed and boosted with two distinct viral vectors expressing the same plasmodial antigen. Proceedings of the National Academy of Sciences of the United States of America, 2001, Sep-25, Volume: 98, Issue:20 Topics: Animals; Antibody Formation; Antimalarials; BCG Vaccine; Disease Models, Animal; Fibrosis; Humans; I	2001
Antimycobacterial activity of 5-arylidene aromatic derivatives of hydantoin. Farmaco (Societa chimica italiana : 1989), 2002, Volume: 57, Issue:5 Topics: Animals; Antitubercular Agents; Benzylidene Compounds; Chlorocebus aethiops; Disease Models, Animal;	2002
[Effect of cyclophosphamide on experimental tuberculosis in mice]. Annales de microbiologie, 1978, Volume: 129, Issue:1 Topics: Acute Disease; Animals; BCG Vaccine; Chronic Disease; Cyclophosphamide; Disease Models, Animal; Ison	1978
Changes in the pulmonary uptake and binding of drugs in an experimental model of lung fibrosis. Toxicology and applied pharmacology, 1979, Volume: 49, Issue:3 Topics: Animals; Dexamethasone; Disease Models, Animal; Isoniazid; Lung; Male; Paraquat; Penicillin G; Pulmo	1979
Isoniazid hepatitis in adolescents. The Journal of pediatrics, 1976, Volume: 89, Issue:1 Topics: Adolescent; Alanine Transaminase; Animals; Bilirubin; Chemical and Drug Induced Liver Injury; Diseas	1976
[Animal experimental studies on the problem of liver damage by antitubercular agents (rifampicin and isoniazide) by means of the galactosamine model]. Verhandlungen der Deutschen Gesellschaft fur Innere Medizin, 1976, Volume: 82 Pt 1 Topics: Animals; Chemical and Drug Induced Liver Injury; Disease Models, Animal; Galactosamine; Isoniazid; L	1976
[Effect of plasmapheresis on the course of experimental tuberculosis and the tolerance of chemotherapy by patients with renal tuberculosis]. Problemy tuberkuleza, 1992, Issue:7-8 Topics: Animals; Chemical and Drug Induced Liver Injury; Combined Modality Therapy; Disease Models, Animal;	1992
[Use of dimephosphon in pathogenetic therapy of experimental tuberculosis]. Problemy tuberkuleza, 1991, Issue:8 Topics: Animals; Antitubercular Agents; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Admin	1991
[Comparative hepatic toxicity of isoniazid, rifampicin and ethambutol]. Problemy tuberkuleza, 1991, Issue:10 Topics: Animals; Chemical and Drug Induced Liver Injury; Disease Models, Animal; Dose-Response Relationship,	1991
[Effectiveness of tocopherol and anti-hypoxic agents in liver damage caused by antitubercular agents]. Problemy tuberkuleza, 1991, Issue:3 Topics: Animals; Antioxidants; Chemical and Drug Induced Liver Injury; Disease Models, Animal; Hepatitis, An	1991
The pathogenicity of Mycobacterium tuberculosis during chemotherapy. The European respiratory journal, 1990, Volume: 3, Issue:4 Topics: Animals; Anti-Bacterial Agents; Antitubercular Agents; Disease Models, Animal; Drug Therapy, Combina	1990
Combination chemotherapy with ciprofloxacin for infection with Mycobacterium tuberculosis in mouse models. The American journal of medicine, 1989, Nov-30, Volume: 87, Issue:5A Topics: Animals; Ciprofloxacin; Disease Models, Animal; Drug Therapy, Combination; Isoniazid; Male; Mice; Ri	1989
[Effect of isoniazid on experimental epilepsy induced by penicillin]. Taiwan yi xue hui za zhi. Journal of the Formosan Medical Association, 1986, Volume: 85, Issue:2 Topics: Animals; Cats; Disease Models, Animal; Electroencephalography; Epilepsy; Isoniazid; Penicillins	1986
Conduction in unmyelinated fibres in experimental neuropathy. Journal of neurology, neurosurgery, and psychiatry, 1972, Volume: 35, Issue:2 Topics: Acrylamides; Action Potentials; Animals; Disease Models, Animal; Electric Stimulation; Ganglia, Spin	1972
[Induction of Mycobacterium infection by introduction of the organisms into the lung through an intratracheal vinyl tube]. Jikken dobutsu. Experimental animals, 1972, Volume: 21, Issue:2 Topics: Animals; Antibiotics, Antitubercular; Disease Models, Animal; Dust; Ethambutol; Guinea Pigs; Intubat	1972
[Effect of E.coli-L-asparaginase alone or in combination with INH or PAS on the course of experimental tuberculosis in guinea pigs]. Bratislavske lekarske listy, 1972, Dec-06, Volume: 58, Issue:6 Topics: Aminosalicylic Acids; Animals; Asparaginase; Disease Models, Animal; Drug Synergism; Escherichia col	1972
Efficacy of bacillus Calmette-Guérin and isoniazid-resistant bacillus Calmette-Guérin with and without isoniazid chemoprophylaxis from day of vaccination. I. Experimental findings in guinea pigs. The American review of respiratory disease, 1973, Volume: 108, Issue:2 Topics: Animals; Antibody Formation; BCG Vaccine; Disease Models, Animal; Drug Resistance, Microbial; Guinea	1973
Intermittent rifampicin treatment in experimental tuberculosis. Archives roumaines de pathologie experimentales et de microbiologie, 1973, Volume: 32, Issue:2 Topics: Administration, Oral; Agglutination Tests; Animals; Antibodies, Bacterial; Blood Bactericidal Activi	1973
The John Barnwell lecture: Improving existing methods of control of tuberculosis: A prime challenge to the experimentalist. The American review of respiratory disease, 1972, Volume: 105, Issue:2 Topics: Animals; Antitubercular Agents; BCG Vaccine; Biopsy; Disease Models, Animal; Drug Resistance, Microb	1972
A new analogous model for the detection and evaluation of chemotherapeutic products effective in leprosy. Arzneimittel-Forschung, 1972, Volume: 22, Issue:8 Topics: Aniline Compounds; Animals; Dapsone; Disease Models, Animal; Drug Combinations; Ethionamide; Humans;	1972
Bone marrow delta-aminolevulinic acid synthetase activity in experimental sideroblastic anemia. The Journal of laboratory and clinical medicine, 1974, Volume: 84, Issue:1 Topics: 5-Aminolevulinate Synthetase; Anemia, Sideroblastic; Animals; Bone Marrow; Bone Marrow Cells; Cyclos	1974
Antimicrobial activity of the leprostatic drug 3-(p-chloranilino)-10-(p-chlorphenyl-2,10-dihydro-2-(isopropylimino)-phenazine (G 30'320, B. 663). Arzneimittel-Forschung, 1970, Volume: 20, Issue:5 Topics: Animals; Antitubercular Agents; Aspergillosis; Candidiasis; Chloroquine; Cricetinae; Disease Models,	1970
[Experimental tuberculosis in mice, a model for the study of antitubercular chemotherapy]. Archives roumaines de pathologie experimentales et de microbiologie, 1971, Volume: 30, Issue:2 Topics: Animals; Antitubercular Agents; Disease Models, Animal; Drug Resistance, Microbial; Drug Synergism;	1971
Photosensitive epilepsy of the baboon Papio papio. Proceedings of the Royal Society of Medicine, 1972, Volume: 65, Issue:2 Topics: Animals; Disease Models, Animal; Electroencephalography; Epilepsy; Isoniazid; Light; Lysergic Acid D	1972
[Relapse and chemotherapy in experimental mouse tuberculosis]. Kekkaku : [Tuberculosis], 1970, Volume: 45, Issue:6 Topics: Animals; Disease Models, Animal; Isoniazid; Lung; Male; Mice; Spleen; Streptomycin; Tuberculosis	1970
[Influence of isoniazid (INH) on the central nervous system and the antagonism between isoniazid and pyridoxine as well as pantothenic acid and coumarin from Melilotus officinalis in rats]. Arzneimittel-Forschung, 1970, Volume: 20, Issue:11 Topics: Animals; Central Nervous System; Conditioning, Classical; Coumarins; Disease Models, Animal; Isoniaz	1970
[Effect of coumarin from Melilotus officinalis on the convulsion threshold of the central nervous system in rats and guinea pigs]. Arzneimittel-Forschung, 1970, Volume: 20, Issue:11 Topics: Animals; Coumarins; Disease Models, Animal; Guinea Pigs; Isoniazid; Pentylenetetrazole; Plant Extrac	1970
The combination of rifampicin and other antituberculous agents in chronic murine tuberculosis. Chemotherapy, 1971, Volume: 16, Issue:3 Topics: Animals; Cell Count; Chronic Disease; Disease Models, Animal; Drug Synergism; Ethambutol; Ethionamid	1971
Scalable electrophysiology in intact small animals with nanoscale suspended electrode arrays. Nature nanotechnology, 2017, Volume: 12, Issue:7 Topics: Amyotrophic Lateral Sclerosis; Animals; Caenorhabditis elegans; Disease Models, Animal; Electrodes;	2017

isoniazid and Disease Models, Animal